{
"id":"mk19_b_pm_s2",
"subspecialtyId":"pm",
"title":"Airways Disease",
"jsonContent":{
"type":"section",
"id":"mk19_b_pm_s2",
"title":{
"__html":"Airways Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"75f678",
"children":[
"Airways Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_1",
"title":{
"__html":"Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"c3b615",
"children":[
"Asthma"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_1_1",
"title":{
"__html":"Epidemiology and Natural History"
},
"titleNode":{
"type":"section-title",
"hlId":"86b143",
"children":[
"Epidemiology and Natural History"
]
},
"children":[
{
"type":"p",
"hlId":"43327d",
"children":[
"Asthma is an inflammatory disorder of the airways characterized by cough, wheezing, chest tightness, dyspnea, and variable airflow obstruction. Asthma is a major health burden throughout the world; approximately 7.9% of the U.S. population has been diagnosed with asthma, which accounts for 9.6 million office visits per year. Prevalence is increased among patients older than 65 years, women, and persons living below the poverty level. Mortality in asthma is significant, with 9.9 deaths per million Americans caused by asthma in 2017; significantly higher mortality is seen among patients who are older than 65 years."
]
},
{
"type":"p",
"hlId":"1e0c4c",
"children":[
"The onset of asthma can occur at any age, and the natural history varies with the duration and severity of symptoms, sex, and response to therapy. Children often have a family history of atopy or exposure to sensitizing allergens such as dust mites or cockroaches. Childhood asthma may improve or resolve during the teenage and adult years, particularly in males. Adults with new-onset asthma may have occupational exposures known to induce bronchial hyperreactivity. Those with severe symptoms generally have a more sustained course, lower pulmonary function, and increased risk of developing persistent airway obstruction. Diagnosis and treatment of asthma in older adults is often challenged by symptom overlap with other conditions (COPD, heart failure) and the normal effects of aging on pulmonary physiology."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f2ae6c",
"children":[
"Approximately 7.9% of the U.S. population has been diagnosed with asthma, and prevalence is increased among patients older than 65 years, women, and persons living below the poverty level."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_2",
"title":{
"__html":"Pathogenesis"
},
"titleNode":{
"type":"section-title",
"hlId":"1883b2",
"children":[
"Pathogenesis"
]
},
"children":[
{
"type":"p",
"hlId":"56c4c0",
"children":[
"The pathophysiologic mechanisms of asthma include chronic airway inflammation, airway narrowing due to edema, subepithelial fibrosis, smooth muscle hypertrophy, and mucus hypersecretion, in addition to airway smooth muscle constriction causing bronchial hyperreactivity in response to various stimuli. The airway cellular inflammatory profile is variable, persists even during the absence of symptoms, and includes eosinophils, T lymphocytes, mast cells, and neutrophils. Type 2 inflammation with eosinophilia is commonly recognized in allergic asthma, but other cellular profiles exist, with neutrophilic inflammation increasingly recognized in older patients. Bronchial hyperreactivity causing airway obstruction is typically episodic and triggered by stimuli that would not induce symptoms in healthy people. Common triggers include allergens, dusts, fumes, exercise, extremes of temperature, and viral respiratory infections."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_3",
"title":{
"__html":"Risk Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"d811a6",
"children":[
"Risk Factors"
]
},
"children":[
{
"type":"p",
"hlId":"42269f",
"children":[
"Risk factors for asthma include both host and environmental factors. Genes predisposing to atopy, bronchial hyperreactivity, and airway inflammation have been identified, but genetic predisposition is thought to interact with additional factors, including exposure to indoor allergens (mites, furred animals, cockroaches, molds), outdoor allergens (pollens, molds), tobacco smoke, occupational sensitizers and allergens, viral respiratory infections, and air pollution. In addition, obesity is an important risk factor for asthma."
]
},
{
"type":"p",
"hlId":"3c69b0",
"children":[
"Asthma is heterogeneous, but distinct phenotypes are recognized and have implications for underlying mechanisms, treatment, and outcomes. Although specific phenotypes are not yet broadly accepted, many are commonly described. These subsets tend to have different cellular compositions of airway inflammation and may respond variably to anti-inflammatory therapies."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"22f1fd",
"children":[
"Genetic predisposition to asthma is thought to interact with additional factors, including exposure to indoor allergens (mites, furred animals, cockroaches, molds), outdoor allergens (pollens, molds), tobacco smoke, occupational sensitizers and allergens, viral respiratory infections, and air pollution."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_4",
"title":{
"__html":"Symptoms and Clinical Evaluation"
},
"titleNode":{
"type":"section-title",
"hlId":"e4dd57",
"children":[
"Symptoms and Clinical Evaluation"
]
},
"children":[
{
"type":"p",
"hlId":"19a348",
"children":[
"Common symptoms of asthma are cough, wheezing, chest tightness, and shortness of breath. They occur intermittently and in response to various stimuli, including allergens, infections, dusts, fumes, and exercise. Symptoms often have a diurnal variation, worsening in the evening and early morning. Viral respiratory infections are a particularly robust trigger for most patients. Variability of symptoms (both improvement and worsening of symptoms over time) is a key diagnostic feature of asthma."
]
},
{
"type":"p",
"hlId":"c1eeac",
"children":[
"History taking should establish whether the patient has ever smoked tobacco or other products, has pets, or has had environmental exposures to dust, fumes, or particulate matter known to cause bronchial hyperreactivity. A personal or family history of atopy or allergic sinus disease may be present. In particular, the presence of nasal polyps, sensitivity to aspirin, and wheezing is known as the “asthmatic triad.” The physical examination may demonstrate wheezing, reduced airflow, or a prolonged expiratory phase. However, patients may also have a completely normal respiratory exam, particularly when they are symptom-free."
]
},
{
"type":"p",
"hlId":"ad3b6b",
"children":[
"Confirmation of reversible airflow obstruction is a cornerstone of asthma diagnosis and can be assessed by spirometry—with measurement of FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
", FVC, and the FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"/FVC ratio—or by serial measurement of peak expiratory flow rates. Airway obstruction that improves with bronchodilators, improves on subsequent measurements, or improves after 4 weeks of anti-inflammatory treatment supports a diagnosis of asthma. For adults, a significant change in FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" is an increase from baseline of at least 12% and at least 200 mL. For some patients, airflow obstruction is not present during the initial evaluation, and demonstration of bronchial hyperreactivity with bronchial challenge testing is indicated. This is usually performed with inhaled methacholine, although other stimuli (exercise, mannitol) have been validated. If a bronchial challenge test is negative, it is unlikely that a patient has asthma. A positive challenge test confirms bronchial hyperreactivity but is not sufficient to confirm asthma because other disorders may also demonstrate this finding. Therefore, clinical correlation of this finding with symptoms and other testing is needed. Fractional exhaled nitric oxide testing is conditionally recommended as an adjunct in asthma evaluation for those aged 5 years and older. The American Thoracic Society recommends that nitric oxide testing be completed in addition to usual care in patients with asthma in whom treatment is being considered (conditional recommendation). Other potential uses of nitric oxide testing are when the diagnosis of asthma is uncertain after standard evaluation or when spirometry cannot be performed as well as in persistent allergic asthma and uncertainty in choosing, monitoring, or adjusting medications. ."
]
},
{
"type":"p",
"hlId":"6436a7",
"children":[
"A chest radiograph is helpful in many patients to rule out other diagnoses, such as COPD, heart failure, parenchymal lung disorders, central airway obstruction, and bronchiectasis. This is especially important in older adults, in whom asthma is often underrecognized and undertreated."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"92f29f",
"children":[
"Common symptoms of asthma are cough, wheezing, chest tightness, and shortness of breath; they are intermittent and occur in response to various stimuli, including allergens, infections, dusts, fumes, and exercise."
]
},
{
"type":"keypoint",
"hlId":"654ba6",
"children":[
"Confirmation of reversible airflow obstruction with bronchodilators is a cornerstone of asthma diagnosis and can be made by spirometry, with measurement of FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" or FVC showing an increase from baseline of ≥12% and ≥200 mL."
]
},
{
"type":"keypoint",
"hlId":"ebd890",
"children":[
"In patients with clinical symptoms suggestive of asthma but with normal spirometry, bronchial challenge testing (such as with methacholine) may be helpful to evaluate for asthma; a negative test excludes asthma, whereas a positive test requires clinical correlation."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5",
"title":{
"__html":"Asthma Syndromes"
},
"titleNode":{
"type":"section-title",
"hlId":"99c490",
"children":[
"Asthma Syndromes"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_1",
"title":{
"__html":"Allergic Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"7cf3f0",
"children":[
"Allergic Asthma"
]
},
"children":[
{
"type":"p",
"hlId":"746bfd",
"children":[
"Identifying the presence of atopy can determine an allergic asthma phenotype in a patient with respiratory symptoms. The key constituents of the atopic response (activated eosinophils and IgE) are generated by pathways involving cytokines secreted mainly by Th2 cells, and this class of asthmatic airway inflammation is referred to as type 2. It is estimated that at least half of all patients with asthma have type 2 airway inflammation. Biomarker evaluation in these patients often demonstrates serum or sputum eosinophilia or high IgE levels with elevated FeNO. Other common tests to identify atopy include allergy skin-prick tests, which may be administered in the outpatient setting by qualified personnel, and laboratory measurement of allergen-specific IgE in serum. Results of each method are generally concordant. Skin testing is more sensitive but subject to errors related to administration, whereas serum tests are more specific but have higher costs. A normal level of total serum IgE does not preclude clinical allergies. In patients with severe disease, elevated levels of IgE and eosinophils are therapeutic targets for biologic therapies."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_2",
"title":{
"__html":"Cough-Variant Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"730310",
"children":[
"Cough-Variant Asthma"
]
},
"children":[
{
"type":"p",
"hlId":"7c403f",
"children":[
"Patients with asthma whose primary symptom manifestation is chronic cough without other symptoms are considered to have cough-variant asthma. Diagnosis requires documentation of bronchial hyperreactivity, as most patients will have normal baseline spirometry. Recommended therapies are the same as those for other types of asthma. Other causes of chronic cough, including gastroesophageal reflux and upper airway cough syndrome due to rhinitis, should be investigated. Frequently, these etiologies coexist and require concomitant therapy (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s4_2_2",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_3",
"title":{
"__html":"Exercise-Induced Bronchoconstriction"
},
"titleNode":{
"type":"section-title",
"hlId":"4a7c4f",
"children":[
"Exercise-Induced Bronchoconstriction"
]
},
"children":[
{
"type":"p",
"hlId":"69d2d1",
"children":[
"Exercise-induced bronchoconstriction (EIB) refers to acute, measurable airway obstruction that occurs in response to exercise. EIB is one of the most common triggers of symptoms in patients with known asthma, and it also occurs in patients without asthma, typically elite athletes, during periods of high-intensity exercise. Environmental factors play a key role in precipitating symptoms. Exercise in cold, dry air, such as during winter or in indoor ice rinks; exposure to high levels of trichloramines in swimming pools; and inhalation of airborne particulates and ozone have all been implicated."
]
},
{
"type":"p",
"hlId":"2f8ba8",
"children":[
"Other disorders, such vocal cord dysfunction and cardiac disorders, can mimic EIB; therefore, establishing the presence of bronchial hyperreactivity is crucial to making an accurate diagnosis. For most patients this entails bronchial challenge testing with inhaled agents or, ideally, exercise. For safety, guidelines from the Global Initiative for Asthma no longer recommend treatment of asthma, including EIB, with a short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist (SABA) alone. Recommended therapy is either an inhaled glucocorticoid plus SABA when needed or before exercise or low-dose inhaled glucocorticoid-formoterol as needed or before exercise. Nonpharmacologic measures include preexercise warm-up and warming cold air before inhalation (for example, with a mask or scarf)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"b72113",
"children":[
"Initial pharmacologic therapy for exercise-induced bronchoconstriction should consist of administration of an inhaled glucocorticoid plus a short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist or low-dose inhaled glucocorticoid-formoterol when needed or before exercise."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_4",
"title":{
"__html":"Occupational Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"b51b56",
"children":[
"Occupational Asthma"
]
},
"children":[
{
"type":"p",
"hlId":"47eee5",
"children":[
"A careful occupational history is an essential part of asthma evaluation, as it is estimated that 15% of adult asthma is work-related. Occupational asthma includes both asthma that is directly caused by exposure to sensitizing or irritant substances in the workplace and preexisting asthma that is exacerbated by these same factors. Typical sensitizing agents are high-molecular-weight substances, such as proteins, that induce an IgE-mediated immunologic response. Examples include animal and plant allergens, latex, grains, and diisocyanates. Once sensitized, patients may subsequently react to very low levels of exposure. Those at risk include farmers and animal workers, health care workers, latex glove users, bakers, and manufacturers of polyurethane products. A key clinical indicator is the relationship of symptoms to work exposures; patients often improve during weekends and time away from work. Spirometry before and after workplace exposure is a cost-effective way to confirm a suspected diagnosis of occupational asthma. Alternatively, demonstration of bronchial hyperreactivity through bronchial challenge testing or serial peak flow measurements can be used. Treatment consists of reducing exposure to the offending agent through workplace modifications or removing patients from the workplace entirely, in addition to pharmacologic therapy. The overriding principle of treatment should be prevention, which includes workplace interventions to avoid exposures and monitoring for early identification of disease."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"023b1b",
"hvc":true,
"children":[
"A key clinical indicator of occupational asthma is symptom improvement during weekends and time away from work; spirometry before and after workplace exposures is a cost-effective way to confirm a suspected diagnosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_5",
"title":{
"__html":"Reactive Airways Dysfunction Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"c2e5e6",
"children":[
"Reactive Airways Dysfunction Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"eb6d76",
"children":[
"Reactive airways dysfunction syndrome is a well-described subset of irritant-induced occupational asthma. This syndrome occurs in patients without preexisting asthma after a single, high-level exposure to fumes, gases, or vapors; usually the exposure is severe enough to prompt immediate medical evaluation. The diagnosis requires evidence of asthmatic symptoms for at least 3 months after the exposure and is confirmed by airway obstruction or bronchial hyperreactivity."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_6",
"title":{
"__html":"Aspirin-Exacerbated Respiratory Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"5cff42",
"children":[
"Aspirin-Exacerbated Respiratory Disease"
]
},
"children":[
{
"type":"p",
"hlId":"fafb73",
"children":[
"Aspirin-exacerbated respiratory disease describes asthma and rhinosinusitis that are precipitated by exposure to aspirin or other NSAIDs that inhibit cyclooxygenase-1. Clinical characteristics include an onset in adulthood, airway and peripheral eosinophilia, inflammatory sinusitis with polyposis, and persistent, often severe asthma. Ingestion of triggering substances can cause life-threatening bronchospasm within minutes to hours, sometimes accompanied by rhinorrhea, conjunctival injection, and flushing. Chronic management, in addition to the usual stepped asthma care, includes discontinuing all aspirin and NSAIDs and use of leukotriene-receptor antagonists that target the increased leukotriene production implicated in the mechanism of this particular asthma. Aspirin desensitization can improve control in a significant percentage of patients but requires specialized expertise."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_5_7",
"title":{
"__html":"Allergic Bronchopulmonary Aspergillosis"
},
"titleNode":{
"type":"section-title",
"hlId":"8ae4bc",
"children":[
"Allergic Bronchopulmonary Aspergillosis"
]
},
"children":[
{
"type":"p",
"hlId":"0e2f60",
"children":[
"Allergic bronchopulmonary aspergillosis is an ongoing immunologic response to inhaled ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
" species that leads to persistent eosinophilic airway inflammation, increased IgE levels (both total and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
" specific), and eventually tissue damage with airway remodeling. Patients present with difficult-to-control asthma, productive cough, and expectoration of mucus plugs. Radiographs may demonstrate pulmonary infiltrates and bronchiectasis. The diagnostic criteria are debated but include the presence of asthma, elevated IgE levels, positive skin tests to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
" antigens, increased ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
"-specific IgE and IgG levels, and either central bronchiectasis or infiltrates. Management is aimed at suppressing the enhanced immunologic response with systemic glucocorticoids and reducing the fungal antigenic burden with antifungal agents."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_6",
"title":{
"__html":"Management of Chronic Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"27dc53",
"children":[
"Management of Chronic Asthma"
]
},
"children":[
{
"type":"p",
"hlId":"9f44e6",
"children":[
"The goals of longitudinal asthma management are to control chronic asthma symptoms, prevent exacerbations, and minimize risks of developing persistent airway obstruction. This should be accomplished by assessing asthma severity, controlling symptoms on an ongoing basis, and then modifying therapies appropriately, using a stepwise approach ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f03",
"wrapId":"1",
"children":[
"Figure 3"
]
}
]
},
")"
]
},
". There are three essential components to the management of asthma:"
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_pm_f03"
]
},
{
"type":"list",
"ordered":true,
"children":[
" ",
{
"type":"list-item",
"hlId":"bb5cf0",
"children":[
"1. Assessment of symptom control and risk. Standardized, validated questionnaires that can discriminate between well-controlled and inadequately controlled asthma on the basis of patient symptoms include the Asthma Control Test and the Asthma Control Questionnaire. Patients with daytime symptoms less than twice weekly and nocturnal symptoms less than twice monthly during the preceding 4 weeks are considered well controlled. Risk is based on measured lung function and the potential for future exacerbations, which is related to the presence of comorbidities ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t05",
"wrapId":"2",
"children":[
"Table 5"
]
}
]
},
")"
]
},
" and historical features known to predict future exacerbations. Comorbidities such as gastroesophageal reflux disease, sinus disease, obstructive sleep apnea, vocal cord dysfunction, and obesity are common and should be considered and actively managed to reduce symptoms and potentially improve asthma control."
]
},
" ",
{
"type":"list-item",
"hlId":"3ef7bc",
"children":[
"2. Treatment. Once symptoms and risk are established, therapy should be initiated. All patients with asthma should be provided with rescue medication to use as needed for symptoms. Controller medications are used as maintenance therapy to control symptoms and prevent exacerbations. A critical component of this therapy is teaching and assessing proper inhaler technique; patients require skill and training to effectively use these devices. Use of a spacer can be helpful with compatible inhaler devices."
]
},
" ",
{
"type":"list-item",
"hlId":"c23f2c",
"children":[
"3. Review response and adjust therapy. Patients should be reassessed several months after initiation of asthma therapies for their level of control and tolerance of medications. Controller medications can be stepped up or down with the goal of maintaining symptom control and minimizing medication exposure."
]
},
" "
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_pm_t05"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"659510",
"children":[
"Aspirin-exacerbated respiratory disease describes asthma and rhinosinusitis that are precipitated by exposure to aspirin or other NSAIDs that inhibit cyclooxygenase-1."
]
},
{
"type":"keypoint",
"hlId":"4aab0d",
"children":[
"Control of asthma should be assessed with the use of validated questionnaires."
]
},
{
"type":"keypoint",
"hlId":"9b18c1",
"children":[
"Inhaler skills training and adherence are essential for successful treatment."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_6_1",
"title":{
"__html":"Quick-Relief Medication"
},
"titleNode":{
"type":"section-title",
"hlId":"70afa1",
"children":[
"Quick-Relief Medication"
]
},
"children":[
{
"type":"p",
"hlId":"3ea7da",
"children":[
"All patients with asthma should be provided with quick-relief, or rescue, therapy. SABAs are the preferred medications to quickly reverse bronchospasm and relieve acute asthma symptoms; however, new safety information suggests that they should only be used in combination with inhaled glucocorticoids ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t06",
"wrapId":"3",
"children":[
"Table 6"
]
}
]
},
")"
]
},
". SABAs have a rapid onset of action and deliver medications directly through the airways, reducing systemic adverse effects. Their main mechanism of action is induction of airway smooth muscle relaxation using stimulation of β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist receptors. SABAs are generally not administered on a scheduled basis nor as the sole agent. Albuterol is the most commonly used SABA in the United States. While the National Asthma Education and Prevention Program continues to recommend as-needed SABA for intermittent asthma, the Global Initiative for Asthma now recommends that all adults and adolescents with asthma should receive one of three inhaled glucocorticoid combination regimens to reduce the risk for serious exacerbations and to control symptoms:"
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_pm_t06"
]
},
{
"type":"list",
"ordered":true,
"children":[
" ",
{
"type":"list-item",
"hlId":"008507",
"children":[
"1. For mild asthma, an inhaled glucocorticoid-formoterol combination as needed or a low-dose inhaled glucocorticoid whenever a SABA is taken (note that both combinations are off-label use)"
]
},
" ",
{
"type":"list-item",
"hlId":"f8b6e9",
"children":[
"2. A regular inhaled glucocorticoid or inhaled glucocorticoid plus an inhaled long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist (LABA) daily, plus an as-needed SABA"
]
},
" ",
{
"type":"list-item",
"hlId":"7ef167",
"children":[
"3. Maintenance and rescue treatment with inhaled low-dose budesonide plus formoterol"
]
},
" "
]
},
{
"type":"p",
"hlId":"93aaee",
"children":[
"Short-acting inhaled anticholinergics are less effective than SABAs at relieving acute bronchospasm; however, they may be used as adjunctive therapy to SABA treatment in the management of acute exacerbations in the emergency department. This combination has been shown to reduce hospital admission rates."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"060c41",
"children":[
"All patients with asthma should be provided with quick-relief, or rescue, therapy."
]
},
{
"type":"keypoint",
"hlId":"3c965e",
"children":[
"The most recent Global Initiative for Asthma guidelines recommend one of three inhaled glucocorticoid combination regimens: an inhaled glucocorticoid-formoterol combination as needed or low-dose inhaled glucocorticoid whenever a short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist (SABA) is taken; a daily inhaled glucocorticoid or inhaled glucocorticoid plus inhaled long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist, plus an as-needed SABA; or maintenance and rescue treatment with low-dose budesonide-formoterol."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_6_2",
"title":{
"__html":"Controller Medications"
},
"titleNode":{
"type":"section-title",
"hlId":"f06ad7",
"children":[
"Controller Medications"
]
},
"children":[
{
"type":"p",
"hlId":"d09d98",
"children":[
"Controller medications are used to provide ongoing symptom relief and to prevent asthma exacerbations. Several different classes of controllers exist that target different mechanisms of the asthmatic profile; therefore, medications can be effectively combined to achieve good control. The choice of therapy generally depends on the assessment of risk and is adjusted on the basis of symptom response and patient tolerance (see ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f03",
"wrapId":"4",
"children":[
"Figure 3"
]
}
]
},
" and ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t06",
"wrapId":"4",
"children":[
"Table 6"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_pm_f03",
"mk19_b_pm_t06"
]
},
{
"type":"p",
"hlId":"b3a5d5",
"children":[
"Inhaled glucocorticoids are the most effective class of asthma controller medications. These agents alleviate several pathologic processes that make up the asthmatic response, including airway mucosal edema, mucus hypersecretion, and airway inflammation. Adverse effects are dose-related and vary with the steroid formulation. They relate to local deposition (oral candidiasis, dysphonia) and can sometimes be generalized as a result of some degree of systemic absorption. Systemic adverse effects such as adrenocortical suppression, reduced bone mineral density, and cataracts do not generally occur at doses below 400 μg of inhaled budesonide daily or equivalent doses of other inhaled glucocorticoid formulations. An increased rate of pneumonia is found with high-dose and high-potency formulations. Despite these risks, use of inhaled glucocorticoids to prevent the need for oral glucocorticoids should outweigh the potential adverse effects. In active smokers, the effectiveness of these medications is diminished and higher dosing may be required."
]
},
{
"type":"p",
"hlId":"b1773c",
"children":[
"Inhaled LABAs that provide sustained airway dilation with just once- or twice-daily dosing are an important tool for asthma treatment. When added to an inhaled glucocorticoid, they provide improved control and decrease the risk for exacerbation. For patients whose asthma is not adequately controlled by a low- or medium-strength inhaled glucocorticoid and SABA as needed, the recommended next step is the addition of formoterol (a LABA) as combined therapy with an inhaled low-dose glucocorticoid in a single inhaler device. Administration in a single inhaler is preferred because of greater adherence and reduced cost compared with administration of each drug in a separate inhaler. Single-agent use of LABAs is not recommended because of the demonstrated increased risk for asthma-related death when used without a simultaneous controller medication. However, five large clinical trials showed that LABAs, when used with inhaled glucocorticoids, did not significantly increase the risk for asthma-related hospitalization, intubation, or death compared with inhaled glucocorticoids alone, and resulted in significantly fewer asthma exacerbations."
]
},
{
"type":"p",
"hlId":"aa586f",
"children":[
"Leukotriene-receptor antagonists have a modest bronchodilation effect and treat upper airway conditions such as allergic rhinitis. Patients with aspirin-exacerbated respiratory disease often respond well to these agents."
]
},
{
"type":"p",
"hlId":"44090d",
"children":[
"Oral glucocorticoids are a cornerstone of therapy for the treatment of acute asthma exacerbations, but long-term use exposes patients to the well-known adverse effects of these agents (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t06",
"wrapId":"5",
"children":[
"Table 6"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_pm_t06"
]
},
{
"type":"p",
"hlId":"6e06ad",
"children":[
"Long-acting muscarinic antagonists (LAMAs) provide sustained airway dilation, and tiotropium has been shown to improve lung function and reduce exacerbations when added to therapy in patients not controlled with inhaled glucocorticoid–LABA combination therapy. For patients with excessive adverse effects from LABAs, a LAMA can reasonably be substituted. However, there is not substantial evidence that LAMAs, instead of LABAs, should be the first choice for long-acting airway dilation."
]
},
{
"type":"p",
"hlId":"a37bd2",
"children":[
"Newer antibody therapies directed against specific mediators of the asthmatic response can be used in patients with severe asthma not adequately controlled on standard therapy, and they have significantly altered the treatment paradigm for these patients. Several types of biologic therapies are now available, and more are in development. The currently available agents are directed against type 2 inflammation and target pathways involved in the activation of eosinophils and IgE production. It is estimated that at least half of patients with asthma have type 2 airway inflammation. In a process referred to as phenotyping, clinically recognizable characteristics are combined with biomarkers to determine whether patients have type 2 inflammation that could benefit from specific biologic treatments. Clinical characteristics suggesting a type 2 high phenotype include atopy, seasonal exacerbations, hay fever, and allergen sensitization. If patients have atopy, as documented by skin testing or elevated serum allergen-specific IgE with high total IgE levels, they can benefit from the anti-IgE biologic omalizumab. Omalizumab is a monoclonal antibody that binds IgE and has been shown to reduce exacerbations in patients with severe persistent asthma despite therapy with high-dose inhaled glucocorticoid and LABA therapy and, often, additional pharmacologic therapies. Patients with eosinophilia can be treated with inhibitors of interleukins involved in eosinophilic recruitment and maturation. These include mepolizumab, reslizumab, and benralizumab, which target interleukin-5 (IL-5), or dupilumab, an inhibitor of IL-4 and IL-13. The level of blood eosinophilia that predicts efficacy varies for each agent and ranges from an absolute eosinophil count of 150 cells/μL (0.15 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) to 400 cells/μL (0.4 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L), regardless of IgE level."
]
},
{
"type":"p",
"hlId":"cb14fe",
"children":[
"Both anti-IgE and anti-interleukin therapies reduce symptoms, need for oral glucocorticoids, and exacerbations in eligible patients with moderate or severe persistent asthma. These treatments are expensive and should only be considered after verifying patient adherence with asthma medications, assessing inhaler technique, and addressing any comorbid conditions. Nonetheless, omalizumab reduces emergency department visits and may be cost-effective in eligible patients with moderate to severe atopic asthma that is not well controlled with other therapies."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2c0c27",
"children":[
"Inhaled glucocorticoids are the most effective class of asthma controller medications."
]
},
{
"type":"keypoint",
"hlId":"2362f3",
"children":[
"For patients whose asthma is not adequately controlled by a moderate-strength inhaled glucocorticoid, the addition of a long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist as combined therapy with an inhaled low-dose glucocorticoid in a single inhaler device is the recommended next step."
]
},
{
"type":"keypoint",
"hlId":"87d662",
"children":[
"Single-agent use of long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists is not recommended because of the demonstrated increased risk for asthma-related death when used without another controller medication."
]
},
{
"type":"keypoint",
"hlId":"30abfa",
"children":[
"Targeting elevated IgE or eosinophil levels with antibody therapies in eligible patients with severe persistent allergic asthma despite standard therapy reduces symptoms, need for oral glucocorticoids, and exacerbations."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_6_3",
"title":{
"__html":"Nonpharmacologic Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"9a00d5",
"children":[
"Nonpharmacologic Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"e7cc44",
"children":[
"Comprehensive asthma care strategies include avoidance of triggers with allergen management (mold abatement, pest control, air filters), reduced exposure to environmental tobacco smoke, and a healthy diet and exercise program to promote weight loss."
]
},
{
"type":"p",
"hlId":"9f9699",
"children":[
"Bronchial thermoplasty is a radiofrequency airway treatment administered using bronchoscopy that can reduce exacerbations and improve quality of life. Candidates are patients with an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" higher than 60% and severe asthma that is poorly controlled despite high-dose inhaled glucocorticoid–LABA combination therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_7",
"title":{
"__html":"Management of Asthma Exacerbations"
},
"titleNode":{
"type":"section-title",
"hlId":"685f3b",
"children":[
"Management of Asthma Exacerbations"
]
},
"children":[
{
"type":"p",
"hlId":"9a5cae",
"children":[
"Asthma exacerbation refers to an acute worsening of symptoms or lung function from baseline that necessitates a step up in therapy (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f03",
"wrapId":"6",
"children":[
"Figure 3"
]
}
]
},
")"
]
},
". Prompt recognition and treatment of asthma exacerbations are needed to relieve symptoms and prevent hospitalizations. All patients with asthma should have a written asthma management plan that helps them recognize the symptoms of an exacerbation and begin self-treatment. Clinicians should screen for patient factors that contribute to an increased risk for death from asthma and counsel patients appropriately ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t07",
"wrapId":"6",
"children":[
"Table 7"
]
}
]
},
")"
]
},
". Self-treatment of an exacerbation consists of frequent use of reliever medications; increasing the dose, frequency, or both of controller medications; and adding a short course of oral glucocorticoids (typically 5-7 days of prednisone 40-50 mg/d). Patients who do not improve with self-care or who have signs that indicate a severe attack should be evaluated in an acute care facility. Management there should include close monitoring of dyspnea, work of breathing, and vital signs; treatment should include frequent inhaled SABA administration, prompt glucocorticoid therapy, and administration of supplemental oxygen to maintain oxygen saturation above 93%. For further discussion of severe asthma exacerbations, see Common ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s12_1_10_2_3",
"children":[
"ICU Conditions"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_pm_f03",
"mk19_b_pm_t07"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3ffb30",
"children":[
"All patients with asthma should have a written asthma management plan that helps them recognize the symptoms of an exacerbation and begin self-treatment."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_8",
"title":{
"__html":"Severe Refractory Asthma"
},
"titleNode":{
"type":"section-title",
"hlId":"14a6ac",
"children":[
"Severe Refractory Asthma"
]
},
"children":[
{
"type":"p",
"hlId":"e0fdc4",
"children":[
"Severe refractory asthma is present in patients who require high doses of an inhaled glucocorticoid plus a second controller or oral glucocorticoids to prevent worsening, or who experience two or more exacerbations within 1 year that require an emergency department visit or hospitalization. This group of patients consumes the most asthma-related health care resources. It is important to verify the diagnosis in these patients and to document medication compliance and correct inhaler technique before considering additional therapies. In addition, comorbidities should be aggressively managed. Treatment guided by specific phenotypes can be helpful in this group, such as biologic agents for patients with high IgE or eosinophil levels and leukotriene-receptor antagonists for patients with aspirin sensitivity. Referral to a team of subspecialists is often indicated."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_1_9",
"title":{
"__html":"Asthma in Pregnancy"
},
"titleNode":{
"type":"section-title",
"hlId":"6a0e46",
"children":[
"Asthma in Pregnancy"
]
},
"children":[
{
"type":"p",
"hlId":"f46c91",
"children":[
"Pregnant patients should be advised that the advantages of asthma treatment are significantly greater than the potential risk to the fetus from asthma therapies. Pregnancy can affect asthma control, leading to either worsening or improvement, and patients should be closely monitored for signs of exacerbation, which occurs most frequently during the second trimester. Inhaled glucocorticoids, oral glucocorticoids, SABAs, leukotriene-receptor antagonists (montelukast, zafirlukast), and LABAs have all been used extensively during pregnancy without data to suggest fetal harm."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2",
"title":{
"__html":"Chronic Obstructive Pulmonary Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"dffff5",
"children":[
"Chronic Obstructive Pulmonary Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_2_1",
"title":{
"__html":"Definition"
},
"titleNode":{
"type":"section-title",
"hlId":"0b890b",
"children":[
"Definition"
]
},
"children":[
{
"type":"p",
"hlId":"0c3911",
"children":[
"COPD is a chronic lung disease defined by persistent respiratory symptoms and airflow limitation or obstruction that is not fully reversible."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_2",
"title":{
"__html":"Epidemiology"
},
"titleNode":{
"type":"section-title",
"hlId":"7113ad",
"children":[
"Epidemiology"
]
},
"children":[
{
"type":"p",
"hlId":"c83fb1",
"children":[
"COPD is a common disorder that currently affects more than 6% of the U.S. population. The worldwide prevalence continues to rise, and the World Health Organization predicts that by 2030 COPD will become the world's fifth most prevalent disorder and the third leading cause of death. COPD is associated with high morbidity and mortality and is the fourth leading cause of death in the United States."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_3",
"title":{
"__html":"Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"34686e",
"children":[
"Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"047652",
"children":[
"COPD is an inflammatory condition. Cigarette smoke and other irritants activate both macrophages and epithelial cells within the respiratory tract. The epithelial cells then release several neutrophil chemotactic factors. Macrophages and neutrophils release proteases that cause destruction of lung parenchyma. Proteases are typically inactivated by antiproteases, such as α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin, which may also be reduced in COPD. Oxidative stress from irritants and inflammatory cells may lead to additional inflammation and tissue destruction. Ultimately, patients develop fibrosis of the small airways and reduced elastic recoil of the lungs leading to static hyperinflation; in addition, mucin concentrations are abnormally elevated. As the degree of inflammation increases, airflow obstruction worsens and the ability to fully exhale decreases. Inhalation is initiated before exhalation is completed, resulting in dynamic hyperinflation—termed air trapping—which is seen as an increased anteroposterior diameter of the chest and flattening of the diaphragm on chest radiographs. The diaphragmatic flattening limits the ability to increase breath volume during exertion. Compensatory use of accessory muscles to increase tidal volume and increased respiration rate augment minute ventilation. These changes increase the work of breathing and contribute to the sensation of dyspnea in patients with COPD."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_4",
"title":{
"__html":"Risk Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"d811a6",
"children":[
"Risk Factors"
]
},
"children":[
{
"type":"p",
"hlId":"e0333f",
"children":[
"Exposure to cigarette smoke (both first- and secondhand exposure) is the most important risk factor for COPD. Genetic predisposition seems to explain some of the variation in susceptibility to developing COPD when exposed to cigarette smoke. Long-term exposure to other irritants can also result in COPD. This includes exposure to air pollution (both indoor and outdoor) and occupational chemicals and dusts. An important example of indoor air pollution is the use of biomass fuel for cooking inside the home, which is a common risk factor for COPD in the developing world. A family history of COPD is also considered a risk factor for the disease, as is α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3daee7",
"children":[
"Exposure to cigarette smoke is the most important risk factor for COPD."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_5",
"title":{
"__html":"Heterogeneity of COPD"
},
"titleNode":{
"type":"section-title",
"hlId":"77816b",
"children":[
"Heterogeneity of COPD"
]
},
"children":[
{
"type":"p",
"hlId":"049211",
"children":[
"COPD is a heterogeneous condition. Some patients present predominately with a chronic productive cough due to mucus hypersecretion, whereas others present predominately with progressive dyspnea secondary to hyperinflation. The heterogeneity extends beyond clinical symptoms. Phenotypic heterogeneity has been characterized on the basis of clinical, physiologic, molecular, and radiographic variables. For example, eosinophilia has been associated with increased responsiveness to glucocorticoids. There also appears to be a subgroup of patients who are more prone to developing acute exacerbations. Understanding such variables could potentially improve the accurate assessment of prognosis and individualize patient care. Because of the heterogeneity of the disease and its presentation, tools have been developed to aid in determining prognosis and best treatment strategies. Several staging assessments exist. For example, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) system combines the degree of airflow obstruction obtained from spirometry with the number of previous exacerbations as well as symptoms to help determine treatment. The BODE index uses the variables of body mass index (B), airflow obstruction (O), dyspnea (D), and exercise capacity (E) to predict outcomes and response to therapy. Airflow obstruction is determined using the postbronchodilator FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" percentage of predicted value for age, sex, height, and race. The BODE index uses the Modified British Medical Research Council (mMRC) dyspnea scale questionnaire to grade perceived dyspnea ranging from dyspnea only with strenuous exercise to dyspnea even when getting dressed. The exercise capacity is determined by the walking distance on a 6-minute walk test. This index provides better prognostic information than the FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" alone and has been used to approximate 4-year survival and risk for hospitalization for COPD."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_6",
"title":{
"__html":"Comorbid Conditions"
},
"titleNode":{
"type":"section-title",
"hlId":"0d8af2",
"children":[
"Comorbid Conditions"
]
},
"children":[
{
"type":"p",
"hlId":"6609fa",
"children":[
"Patients with COPD often suffer from comorbid conditions that further increase morbidity and mortality. Some conditions, such as cardiovascular disease, share common risk factors, but others seem to be independently associated with COPD or a consequence of treatment of COPD. These include muscle loss with associated weakness and weight loss, osteoporosis, and depression."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"803c7a",
"children":[
"COPD is a heterogeneous condition and patients present with variable symptoms, including cough, sputum production, and dyspnea."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_7",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"64da9b",
"children":[
"The possibility of COPD should be considered and spirometry should be performed in patients aged 40 years or older with progressive dyspnea, chronic cough, chronic sputum production, or recurrent lower respiratory tract infections, particularly in the presence of known risk factors for the disease, especially smoking. The role of screening spirometry in asymptomatic individuals with risk factors is controversial. The U.S. Preventive Services Task Force guideline recommends against screening for COPD in asymptomatic adults, whereas the GOLD advocates performing screening spirometry in individuals with risk factors for COPD."
]
},
{
"type":"p",
"hlId":"fc4bd8",
"children":[
"In the appropriate clinical context, the diagnosis of COPD is made using spirometric measurement to document airflow obstruction. COPD is confirmed by a postbronchodilator FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"/FVC ratio of less than 0.70. This differs from the finding in patients with asthma, whose airflow obstruction is reversible with bronchodilator therapy. Measuring lung volumes and diffusing capacity is not required to diagnose COPD but may help in determining the severity of disease. Clinicians should rule out other causes of chronic respiratory symptoms, including heart failure, bronchiectasis, obliterative bronchiolitis, tuberculosis, and diffuse panbronchiolitis."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"039c52",
"children":[
"The U.S. Preventive Services Task Force guideline does not recommend spirometric screening for COPD in asymptomatic individuals."
]
},
{
"type":"keypoint",
"hlId":"a31c3e",
"children":[
"In the appropriate clinical context, COPD is diagnosed by a postbronchodilator FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"/FVC ratio of less than 0.70."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_8",
"title":{
"__html":"Disease Assessment"
},
"titleNode":{
"type":"section-title",
"hlId":"d46213",
"children":[
"Disease Assessment"
]
},
"children":[
{
"type":"p",
"hlId":"a9bb47",
"children":[
"After a diagnosis of COPD has been established, the initial assessment focuses on disease severity, which is determined using a combination of symptoms, degree of airflow obstruction on spirometry, history of acute exacerbations, and presence of comorbid conditions. Several validated tools are available to assess patients' symptoms, including the COPD Assessment Test, the Clinical COPD Questionnaire, and the mMRC scale ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t08",
"wrapId":"7",
"children":[
"Table 8"
]
}
]
},
")"
]
},
". The GOLD criteria use the COPD Assessment Test or mMRC scale to determine symptom severity, and the BODE index ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t09",
"wrapId":"7",
"children":[
"Table 9"
]
}
]
},
")"
]
},
" requires the use of the mMRC scale. The Clinical COPD Questionnaire is often used to screen patients for symptoms of COPD. Symptoms are then combined with the results from spirometry ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t10",
"wrapId":"7",
"children":[
"Table 10"
]
}
]
},
")"
]
},
" to determine disease severity ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t11",
"wrapId":"7",
"children":[
"Table 11"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_pm_t08",
"mk19_b_pm_t09",
"mk19_b_pm_t10",
"mk19_b_pm_t11"
]
},
{
"type":"p",
"hlId":"87f9e5",
"children":[
"Patients who have had two or more acute exacerbations within the last year, who have an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" of less than 50% of predicted, or who have ever been hospitalized for an acute exacerbation are at high risk for recurrent acute exacerbations. Clinicians should determine whether the patient suffers from any of the common comorbid conditions associated with COPD that indicate a higher morbidity and mortality and treat appropriately."
]
},
{
"type":"p",
"hlId":"fd0067",
"children":[
"Pulse oximetry at rest and at exertion should be used to determine the need for supplemental oxygen. Arterial blood gases should be measured to assess for underlying hypercapnia in patients with a low FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
", change in mental status, acute exacerbation, elevated level of serum bicarbonate, or oxygen saturation of less than 92% on pulse oximetry."
]
},
{
"type":"p",
"hlId":"512634",
"children":[
"An α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin level should be obtained once in all patients with COPD. A pattern of basilar emphysema, associated liver disease or panniculitis, or a strong family history of emphysema in patients with COPD suggests possible α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency, but none of these features is sufficiently sensitive for the condition."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"222680",
"children":[
"After a diagnosis of COPD has been established, the initial assessment focuses on disease severity, which is determined using a combination of symptoms, degree of airflow obstruction on spirometry, history of acute exacerbations, and presence of comorbid conditions."
]
},
{
"type":"keypoint",
"hlId":"9e0272",
"children":[
"Patients who have had two or more acute exacerbations within the last year, who have an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" of less than 50% of predicted, or who have ever been hospitalized for an acute exacerbation are considered to be at high risk for recurrent acute exacerbations."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9",
"title":{
"__html":"Management of COPD"
},
"titleNode":{
"type":"section-title",
"hlId":"3a3630",
"children":[
"Management of COPD"
]
},
"children":[
{
"type":"p",
"hlId":"5ed95d",
"children":[
"A management plan for COPD should include the identification and reversal of risk factors, especially ongoing exposure to cigarette smoke. The severity of a patient's COPD should guide the choice of therapy ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t12",
"wrapId":"8",
"children":[
"Table 12"
]
}
]
},
")"
]
},
". No currently available treatments can prevent long-term decline in lung function, so patients should be monitored for evidence of disease progression that may guide additional therapy. The goals of therapy are to reduce symptoms and improve exercise tolerance and quality of life, as well as to prevent and treat exacerbations, prevent disease progression, and decrease mortality."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_pm_t12"
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_1",
"title":{
"__html":"Smoking Cessation"
},
"titleNode":{
"type":"section-title",
"hlId":"226ccb",
"children":[
"Smoking Cessation"
]
},
"children":[
{
"type":"p",
"hlId":"daa588",
"children":[
"Smoking cessation is essential in the management of COPD, as it can slow the decline of FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
". Clinicians should encourage patients to quit smoking and be aware that the success rates for smoking cessation increase when counseling is combined with medication therapy. All smokers without contraindications should additionally receive at least one of the seven FDA-approved treatments for smoking cessation. The approved medications include nicotine replacement therapies, varenicline, and bupropion (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s9_5_1",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
")."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"cd2ac6",
"children":[
"Smoking cessation is essential in the management of COPD, as it can slow the decline of FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2",
"title":{
"__html":"Pharmacologic Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"6951bd",
"children":[
"Pharmacologic Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"fdfd61",
"children":[
"Pharmacologic therapies in COPD are used to reduce symptoms, improve quality of life, and reduce the frequency and severity of exacerbations ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t13",
"wrapId":"9",
"children":[
"Table 13"
]
}
]
},
")"
]
},
". Bronchodilators are mainstays of therapy for COPD irrespective of the severity of the disease. Any time bronchodilators or other inhalers are prescribed, the clinician should ensure that the patient receives education on proper inhaler technique. Recommended initial management is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t12",
"wrapId":"9",
"children":[
"Table 12"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_pm_t13",
"mk19_b_pm_t12"
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_1",
"title":{
"__html":"Bronchodilators"
},
"titleNode":{
"type":"section-title",
"hlId":"8313e7",
"children":[
"Bronchodilators"
]
},
"children":[
{
"type":"p",
"hlId":"e4b221",
"children":[
"Inhaled bronchodilators include β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists and anticholinergics/antimuscarinic agents. Both are available as short-acting and long-acting inhalers and improve symptoms and expiratory airflow. SABAs and muscarinic antagonists result in similar bronchodilation, and either can be used as monotherapy. However, dual treatment results in a greater degree of bronchodilation and expiratory airflow, which may lead to symptom benefit in select patients."
]
},
{
"type":"p",
"hlId":"26cfed",
"children":[
"If short-acting bronchodilators are insufficient to control symptoms in patients with more severe disease, a long-acting bronchodilator—either a LABA or a LAMA—can be added. Choosing the appropriate long-acting bronchodilator inhaler requires consideration of patient and physician preference, potential adverse effects, and cost. If symptoms persist on monotherapy, the addition of a second long-acting bronchodilator from the alternate bronchodilator class may result in clinical improvement. Long-acting bronchodilators alone should not be used in patients with a history or diagnosis of asthma unless an inhaled glucocorticoid is also prescribed because of the potential for increased risk for mortality in this patient population when a LABA is used without an inhaled glucocorticoid."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_2",
"title":{
"__html":"Inhaled Glucocorticoids"
},
"titleNode":{
"type":"section-title",
"hlId":"91da21",
"children":[
"Inhaled Glucocorticoids"
]
},
"children":[
{
"type":"p",
"hlId":"db80d0",
"children":[
"Inhaled glucocorticoids are typically used only in combination with a long-acting bronchodilator for treatment of COPD (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t12",
"wrapId":"10",
"children":[
"Table 12"
]
}
]
},
")"
]
},
". Inhaled glucocorticoids are not used alone unless a patient is not able to use long-acting bronchodilators (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t13",
"wrapId":"10",
"children":[
"Table 13"
]
}
]
},
")"
]
},
". Inhaled glucocorticoids used alone and in combination with long-acting bronchodilators improve lung function and reduce symptoms and exacerbations in patients with moderate to severe COPD, but they are associated with an increased risk for pneumonia. In patients with severe COPD, triple inhaler therapy with a LABA, a LAMA, and an inhaled glucocorticoid may provide additional symptom benefit and reduced exacerbations."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_pm_t12",
"mk19_b_pm_t13"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"71c9cc",
"children":[
"Bronchodilators are the mainstay of therapy for COPD irrespective of the severity of the COPD."
]
},
{
"type":"keypoint",
"hlId":"41d534",
"children":[
"Any time bronchodilators or other inhalers are prescribed, the clinician should ensure that the patient receives education on proper inhaler technique."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_3",
"title":{
"__html":"Oral Glucocorticoids"
},
"titleNode":{
"type":"section-title",
"hlId":"b028f5",
"children":[
"Oral Glucocorticoids"
]
},
"children":[
{
"type":"p",
"hlId":"265b8b",
"children":[
"Oral glucocorticoids are recommended for short-duration treatment of acute exacerbations of COPD (see ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s2_2_10_4",
"children":[
"Acute Exacerbations: Goals and Therapeutic Management"
]
},
" section). However, long-term use of oral glucocorticoids should be avoided because of the risk for significant adverse effects, including diabetes and osteoporosis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_4",
"title":{
"__html":"Methylxanthines"
},
"titleNode":{
"type":"section-title",
"hlId":"d6e4fb",
"children":[
"Methylxanthines"
]
},
"children":[
{
"type":"p",
"hlId":"8026e6",
"children":[
"The methylxanthines (aminophylline and theophylline) are now rarely used to treat COPD. Theophylline has been shown to improve functional capacity and reduce the number of exacerbations. However, it has a narrow window between therapeutic and toxic dosages and is therefore only used for patients with advanced COPD who have refractory symptoms not controlled by standard therapy. Studies of the use of either aminophylline or theophylline during acute exacerbations have shown no benefit."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_5",
"title":{
"__html":"Roflumilast"
},
"titleNode":{
"type":"section-title",
"hlId":"41b167",
"children":[
"Roflumilast"
]
},
"children":[
{
"type":"p",
"hlId":"cc361a",
"children":[
"Roflumilast is a selective phosphodiesterase-4 inhibitor that is used to reduce the frequency of exacerbations in patients with severe COPD who have primarily symptoms of chronic bronchitis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_6",
"title":{
"__html":"α<sub>1</sub>-Antitrypsin Augmentation Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"06ecfb",
"children":[
"α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-Antitrypsin Augmentation Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"70d6e9",
"children":[
"Antiproteases, including α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin, typically inactivate proteases that may lead to permanent lung injury. In patients with α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency, replacing this enzyme with augmentation therapy may slow the progression of related emphysema. However, it is costly, has not been shown to decrease exacerbations or the rate of FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" decline, and is not effective for the treatment of patients whose COPD is not caused by α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_7",
"title":{
"__html":"Other Agents"
},
"titleNode":{
"type":"section-title",
"hlId":"6cfb6a",
"children":[
"Other Agents"
]
},
"children":[
{
"type":"p",
"hlId":"32e956",
"children":[
"Macrolide antibiotics have anti-inflammatory and antimicrobial effects. Long-term macrolide therapy may reduce the frequency of exacerbations when prescribed for patients with severe COPD and a history of frequent exacerbations. Mucolytics and antitussives are not routinely used in the management of COPD but may provide some symptomatic relief in patients with significant sputum production."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_2_8",
"title":{
"__html":"Immunization"
},
"titleNode":{
"type":"section-title",
"hlId":"a3bca2",
"children":[
"Immunization"
]
},
"children":[
{
"type":"p",
"hlId":"6f82aa",
"children":[
"Immunizations can prevent infections in patients with COPD. Because infections are the most common trigger of acute exacerbations, routine immunizations are recommended for all patients with COPD, including annual influenza vaccination. Regardless of age, patients with COPD who have not previously received a pneumococcal conjugate vaccine or whose vaccination history is unclear should receive either the 20-valent pneumococcal conjugate vaccine (PCV20) alone or the 15-valent pneumococcal conjugate vaccine (PCV15) followed by the pneumococcal polysaccharide vaccine (PPSV23) at least 1 year later. (See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3",
"children":[
"MKSAP 19 General Internal Medicine 2: Routine Care of the Healthy Patient/Immunization"
]
},
" section.)"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"98c49a",
"children":[
"Oral glucocorticoids are recommended for short-duration treatment of acute exacerbations of COPD; long-term use of oral glucocorticoids should be avoided."
]
},
{
"type":"keypoint",
"hlId":"958ae2",
"children":[
"All patients with COPD should have the pneumococcal polysaccharide vaccine and an annual influenza immunization."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_3",
"title":{
"__html":"Nonpharmacologic Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"9a00d5",
"children":[
"Nonpharmacologic Therapy"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_3_1",
"title":{
"__html":"Pulmonary Rehabilitation"
},
"titleNode":{
"type":"section-title",
"hlId":"a102ab",
"children":[
"Pulmonary Rehabilitation"
]
},
"children":[
{
"type":"p",
"hlId":"7b18cc",
"children":[
"Pulmonary rehabilitation is a comprehensive program that combines exercise training, nutritional support, education, and social support for patients with chronic lung conditions. It has been shown to relieve symptoms, improve quality of life, and decrease frequency of hospitalizations in patients with COPD. Clinicians should consider adding this to appropriate medical therapy in patients with a GOLD severity group of B, C, or D, and particularly in those recently hospitalized after an exacerbation."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_3_2",
"title":{
"__html":"Oxygen Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"bfe5a7",
"children":[
"Oxygen Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"cbb88c",
"children":[
"The use of supplemental oxygen has been shown to improve quality of life and decrease mortality in patients with COPD and resting hypoxemia with an arterial P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"O"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" of 55 mm Hg or less or an oxygen saturation (as measured by pulse oximetry) of 88% or less. Patients with cor pulmonale, heart failure, or erythrocytosis should be offered the use of supplemental oxygen if their P",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"O"
]
},
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" is 59 mm Hg or less or their oxygen saturation is 89% or less. Some patients may not qualify for oxygen at rest but may desaturate during sleep, exertion, or air travel. Supplemental oxygen is typically prescribed if the oxygen saturation as measured by pulse oximetry falls below 89% in these situations, but the benefits are less defined."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_3_3",
"title":{
"__html":"Noninvasive Positive Pressure Ventilation"
},
"titleNode":{
"type":"section-title",
"hlId":"fedfd2",
"children":[
"Noninvasive Positive Pressure Ventilation"
]
},
"children":[
{
"type":"p",
"hlId":"856902",
"children":[
"Noninvasive positive pressure ventilation (NPPV), also termed noninvasive mechanical ventilation, can be used for acute and chronic respiratory failure. For patients with a COPD exacerbation and acute hypercapnic respiratory failure with acidosis, NPPV improves symptoms and reduces intubation rates, lengths of hospital stay, and mortality. It may also be beneficial in patients with COPD who have pneumonia to help with discontinuing mechanical ventilation and for palliative care. It does not replace intubation and mechanical ventilation in critically ill patients, comatose patients, or patients who have sustained a cardiac arrest. NPPV is generally well tolerated, and improvement of the pH and Pco",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" within 1 to 2 hours predicts success. Adding home NPPV to oxygen therapy in patients with persistent hypercapnia after an acute exacerbation of COPD prolongs the time to readmission and death."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_4",
"title":{
"__html":"Prognosis and Goals of Care"
},
"titleNode":{
"type":"section-title",
"hlId":"8bd22c",
"children":[
"Prognosis and Goals of Care"
]
},
"children":[
{
"type":"p",
"hlId":"a4cb4d",
"children":[
"The current GOLD initiative recommends combining the degree of airflow limitation using the postbronchodilator FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" with the number of exacerbations and the patient's symptoms to classify the severity of disease. This will allow the clinician to guide escalation or deescalation of medical therapies as appropriate (see Tables 10, 11, and 12)."
]
},
{
"type":"p",
"hlId":"ee8bc6",
"children":[
"The BODE index (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t09",
"wrapId":"11",
"children":[
"Table 9"
]
}
]
},
")"
]
},
" can be used as a prognostic indicator for patients with COPD to approximate 4-year survival."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_pm_t09"
]
},
{
"type":"p",
"hlId":"cfdc54",
"children":[
"In patients with severe disease with an overall poor prognosis, referral for palliative care or hospice can provide significant improvements in symptom burden. Palliative care can significantly aid in symptom management in patients with COPD at any stage of disease. Patients experience not only dyspnea but also anxiety and depression, which may also be addressed. Opioids are commonly used to treat dyspnea that persists despite medical therapy. Guidelines suggest a patient with severe COPD—defined by disabling symptoms despite medical therapy, progression of disease as evidenced by increasing emergency department evaluations or hospitalizations, and hypoxemia or hypercapnia—should be considered for hospice care."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"b54a2a",
"children":[
"Guidelines suggest that a patient with severe COPD (defined by disabling symptoms despite medical therapy, progression of disease as evidenced by increasing emergency department evaluations or hospitalizations, and hypoxemia or hypercapnia) should be considered for hospice care."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_4_1",
"title":{
"__html":"Lung Volume Reduction Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"356121",
"children":[
"Lung Volume Reduction Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"9ae173",
"children":[
"The National Emphysema Treatment Trial demonstrated that patients with upper-lobe-predominant emphysema and significant exercise limitations even after participation in a pulmonary rehabilitation program had improved quality of life, exercise tolerance, pulmonary function, and survival with lung volume reduction surgery. A key finding from the National Emphysema Treatment Trial was that patient selection was critical to success and that patients with an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" of less than 20% of predicted, a diffusing capacity of less than 20% of predicted, or non-upper-lobe-predominant disease had a high operative mortality and should not be offered lung volume reduction surgery. Nonsurgical lung volume reduction procedures, including bronchoscopic placement of endobronchial valves or plugs and thermal ablation of the airway, are being studied for treatment of emphysematous changes in patients with COPD. Early results suggest that patients with severe air trapping and hyperinflation may get the most benefit from these new techniques. Patient selection criteria for surgical lung volume reduction also apply to nonsurgical techniques."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_9_4_2",
"title":{
"__html":"Lung Transplantation"
},
"titleNode":{
"type":"section-title",
"hlId":"55832f",
"children":[
"Lung Transplantation"
]
},
"children":[
{
"type":"p",
"hlId":"45e837",
"children":[
"Referral for lung transplantation can be considered in patients with severe COPD. The decision to refer should depend on the patient's life expectancy, quality of life, and preferences. In general, patients at high risk of dying in less than 2 years who have a high probability of 90-day postoperative survival are candidates. Patients with an elevated BODE index (5 or 6), resting hypoxemia, hypercapnia, an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" of less than 25% of predicted, or significant exercise limitation despite medical therapy, smoking cessation, and participation in a pulmonary rehabilitation program may be referred for evaluation for lung transplantation. Transplantation improves quality of life, and the median life expectancy is 5.5 years."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_10",
"title":{
"__html":"Acute Exacerbations"
},
"titleNode":{
"type":"section-title",
"hlId":"1ba3c2",
"children":[
"Acute Exacerbations"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_2_10_1",
"title":{
"__html":"Definition"
},
"titleNode":{
"type":"section-title",
"hlId":"0b890b",
"children":[
"Definition"
]
},
"children":[
{
"type":"p",
"hlId":"1d37c2",
"children":[
"An acute exacerbation of COPD is a worsening of a patient's typical symptoms that leads to a change in medical therapy or requires hospitalization. Most commonly, exacerbations are manifested by an increase in the severity or frequency of cough, worsening dyspnea, and an increase in the amount or change in the character of sputum produced. Most exacerbations are triggered by a respiratory infection (either viral or bacterial), smoking, and environmental exposures. An exacerbation can be triggered by other causes, and in some cases no trigger is identified. Studies suggest that exacerbations are underreported by patients and result in adverse outcomes."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1cdaa5",
"children":[
"An acute exacerbation of COPD is a change in a patient's typical symptoms that leads to a change in medical therapy or hospitalization; the most common symptoms of exacerbations are an increase in the severity or frequency of cough, worsening dyspnea, and an increase in the amount or change in the character of sputum produced."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_10_2",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"b26a95",
"children":[
"Acute exacerbations of COPD can have substantial effects on quality of life and health care costs, and they may accelerate the decline in lung function and increase mortality. It is therefore important to prevent exacerbations whenever possible. Strategies to prevent exacerbations include smoking cessation, participating in pulmonary rehabilitation programs when appropriate, receiving recommended immunizations, and ensuring proper inhaler technique and use of medications. Long-term use of azithromycin or roflumilast has also been shown to prevent future exacerbations in patients who have a history of frequent exacerbations."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"64c46a",
"children":[
"Strategies to prevent COPD exacerbations include smoking cessation, participating in pulmonary rehabilitation programs when appropriate, receiving recommended immunizations, and ensuring proper inhaler technique and use of medications."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_10_3",
"title":{
"__html":"Initial Assessment and Setting of Care"
},
"titleNode":{
"type":"section-title",
"hlId":"c3c4c3",
"children":[
"Initial Assessment and Setting of Care"
]
},
"children":[
{
"type":"p",
"hlId":"e90ac5",
"children":[
"The first steps in managing a patient with a presumed COPD exacerbation are to confirm the diagnosis and determine the severity of the exacerbation. A mild exacerbation is one that can be managed solely by short-acting bronchodilators. A moderate exacerbation requires treatment with antibiotics, glucocorticoids, or both. A severe exacerbation is defined by the need for an evaluation in the emergency department or hospitalization. Patients with respiratory distress or who are at risk of developing respiratory distress should be hospitalized; additional testing, including a chest radiograph, electrocardiogram, complete blood count, and basic metabolic panel, should be obtained to rule out other causes or comorbidities contributing to the acute presentation. Oxygen saturation should be measured by pulse oximetry. Arterial blood gas measurement is recommended for patients with a severe exacerbation to determine the presence of hypercapnia or hypoxemia. A sputum culture is not routinely used to assess COPD exacerbations as it rarely affects management. Patients with mild symptoms may not require any additional testing."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c28480",
"children":[
"Patients who have COPD and respiratory distress or who are at risk of developing respiratory distress should be hospitalized and evaluated with a chest radiograph, electrocardiogram, complete blood count, basic metabolic panel, and oxygen saturation; arterial blood gas measurements can determine the presence of hypercapnia or hypoxemia."
]
},
{
"type":"keypoint",
"hlId":"eaf67d",
"hvc":true,
"children":[
"A sputum culture is not routinely used to assess COPD exacerbations, as it rarely affects management."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_2_10_4",
"title":{
"__html":"Goals and Therapeutic Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fc9290",
"children":[
"Goals and Therapeutic Management"
]
},
"children":[
{
"type":"p",
"hlId":"0669a3",
"children":[
"The management goals during an acute COPD exacerbation are to relieve acute symptoms and to prevent future exacerbations. Supplemental oxygen should be used to maintain oxygen saturation between 88% and 92%. Noninvasive positive pressure ventilation may be required if oxygenation or ventilation cannot be maintained. Patients may require intubation and mechanical ventilation if they cannot tolerate NPPV, have an altered mental status, or have worsening hypercapnic or hypoxemic respiratory failure despite the use of NPPV. SABAs with or without anticholinergic agents should be used to relieve acute symptoms. The use of oral glucocorticoids during acute exacerbations has been shown to decrease the frequency of treatment failures, length of stay, and time to subsequent exacerbations while improving FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" and hypoxemia. Glucocorticoids have also been shown to decrease the need for hospitalization if used early. Randomized trials have demonstrated that short courses of lower-dose oral prednisone (40 mg for 5 days) are usually equivalent to longer courses, higher doses, and intravenous administration."
]
},
{
"type":"p",
"hlId":"3838fb",
"children":[
"Antibiotics should be prescribed for 5 to 7 days in cases of moderate or severe exacerbations or for patients with mild exacerbations who have noted an increase or change in sputum production. A 2020 systemic review and meta-analysis showed that for mild to severe COPD exacerbations, antibiotics and oral glucocorticoids reduced treatment failure. The most common infectious triggers are viruses, but bacterial causes include ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Streptococcus pneumoniae"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus influenzae"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Moraxella catarrhalis"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycoplasma pneumoniae"
]
},
". If the patient is still smoking, treatment should also focus on smoking cessation because this can prevent future exacerbations. Because the prevalence of pulmonary embolism is higher in patients with COPD, a thromboembolic event should be considered as a potential trigger if patients do not improve with typical therapies for a COPD exacerbation, and appropriate testing should be performed."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3",
"title":{
"__html":"Bronchiectasis"
},
"titleNode":{
"type":"section-title",
"hlId":"c119ec",
"children":[
"Bronchiectasis"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s2_3_1",
"title":{
"__html":"Definition"
},
"titleNode":{
"type":"section-title",
"hlId":"0b890b",
"children":[
"Definition"
]
},
"children":[
{
"type":"p",
"hlId":"dc5449",
"children":[
"Bronchiectasis is a chronic suppurative lung disease associated with irreversible enlargement of the airways due to destruction of airway architecture. An injury to the lung typically results in prolonged airway inflammation, which leads to localized injury with subsequent mucus stasis, which can lead to further airway obstruction, chronic infection, and inflammation with worsening bronchiectasis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3_2",
"title":{
"__html":"Causes"
},
"titleNode":{
"type":"section-title",
"hlId":"82887a",
"children":[
"Causes"
]
},
"children":[
{
"type":"p",
"hlId":"b82952",
"children":[
"In many cases of bronchiectasis, an underlying cause is not identified. The most common causes of bronchiectasis include cystic fibrosis, aspiration, immunodeficiencies, and connective tissue diseases ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t14",
"wrapId":"12",
"children":[
"Table 14"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_pm_t14"
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3_3",
"title":{
"__html":"Presentation"
},
"titleNode":{
"type":"section-title",
"hlId":"c7bc3f",
"children":[
"Presentation"
]
},
"children":[
{
"type":"p",
"hlId":"8ab393",
"children":[
"Bronchiectasis should be considered in the differential diagnosis of any patient with a chronic cough, especially if the patient has a history of frequent respiratory infections or if the cough is productive. Other possible symptoms include hemoptysis, wheezing, and chest pain. Features that should alert the clinician to consider bronchiectasis, especially without significant smoking history, include clubbing and previous sputum cultures growing uncommon pathogens such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas aeruginosa"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Aspergillus"
]
},
", or nontuberculous mycobacteria."
]
},
{
"type":"p",
"hlId":"636192",
"children":[
"Patients with bronchiectasis may also present with extrapulmonary symptoms, especially fatigue."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3_4",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"d89f1f",
"children":[
"Initial evaluation should include a comprehensive medical history, including childhood diseases, family history, and careful evaluation to exclude known causes of bronchiectasis. Bronchiectasis is diagnosed by high-resolution chest CT. Diagnostic criteria include an airway diameter that is greater than that of its accompanying vessel and lack of distal airway tapering ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f04",
"wrapId":"13",
"children":[
"Figure 4"
]
}
]
},
")"
]
},
". Bronchial wall thickening or cysts may be present. For every diagnosed patient, it should be determined whether there is an underlying cause that can be treated. This may involve testing for chronic bacterial or mycobacterial infections. These tests can identify causes of disease progression and help determine targeted antimicrobial therapy for exacerbations. Patients should also be evaluated for the presence of connective tissue disease and immune function. In selected patients, testing for cystic fibrosis, ciliary dysfunction, or α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antitrypsin deficiency may be appropriate. However, even with rigorous evaluation, more than half of all cases are labeled idiopathic."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_pm_f04"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"3d1ea7",
"children":[
"In acute COPD exacerbations, 40 mg prednisone for 5 days has been shown to decrease the frequency of treatment failures, length of stay, and time to subsequent exacerbations while improving FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" and hypoxemia."
]
},
{
"type":"keypoint",
"hlId":"a7b4a9",
"children":[
"Bronchiectasis is diagnosed by high-resolution chest CT; diagnostic criteria include airway diameter greater than that of its accompanying vessel and lack of distal airway tapering."
]
},
{
"type":"keypoint",
"hlId":"1910d8",
"children":[
"For every patient diagnosed with bronchiectasis, it should be determined whether there is an underlying cause that can be treated."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3_5",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"d3f384",
"children":[
"The presence of chronic symptoms of cough and sputum production typically indicates irreversible airway dilation. Therefore, treatment of the underlying cause may not lead to improvement in current symptoms but could prevent further progression. Otherwise, treatment of bronchiectasis focuses on clearing the airway, treating infections, and preventing exacerbations. The goal of airway clearance is to improve mucous clearance and thereby prevent chronic or recurrent infections. Bronchodilators, inhaled glucocorticoids, and combination inhalers have been shown to decrease symptoms but have no effect on the decline of lung function or frequency of exacerbations. Studies suggest that long-term use of macrolide antibiotics may prevent future exacerbations as a result of their anti-inflammatory effects. When deciding whether to use macrolide antibiotics, the risk for future exacerbations should be weighed against the possibility of developing macrolide resistance. Antibiotics may also be used in the management of chronic non-cystic-fibrosis bronchiectasis to eradicate organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"P. aeruginosa"
]
},
" or methicillin-resistant ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Staphylococcus aureus"
]
},
". If eradication of bacterial colonization is not successful, there may be some symptomatic benefit from suppressive therapy with inhaled antibiotics. Patients should also be encouraged to exercise, which can improve airway clearance and symptoms. Surgical resection should be considered in patients who have localized disease with persistent symptoms despite therapy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"388d50",
"children":[
"Identification and treatment of underlying causes of bronchiectasis should be initiated if possible."
]
},
{
"type":"keypoint",
"hlId":"f4ab47",
"children":[
"Treatment of bronchiectasis focuses on clearing the airway, treating infections, and preventing exacerbations."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_3_5_1",
"title":{
"__html":"Treatment of Exacerbations"
},
"titleNode":{
"type":"section-title",
"hlId":"6a39e7",
"children":[
"Treatment of Exacerbations"
]
},
"children":[
{
"type":"p",
"hlId":"edb6c8",
"children":[
"Exacerbations of bronchiectasis may be difficult to differentiate from baseline symptoms. However, changes in sputum volume, viscosity, or purulence; increased cough; wheezing; shortness of breath; hemoptysis; or declines in lung function are considered evidence of an exacerbation. Therapy for an exacerbation is ideally guided by routine sputum and acid-fast bacilli culture results to identify a possible predominant organism for treatment. Empiric antibiotic therapy is recommended and may be based on previous culture data until the results of the current sputum culture become available. If previous data are not available, a fluoroquinolone can be started to ensure ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pseudomonas"
]
},
" coverage until sputum culture results are available."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_4",
"title":{
"__html":"Cystic Fibrosis"
},
"titleNode":{
"type":"section-title",
"hlId":"7dc6de",
"children":[
"Cystic Fibrosis"
]
},
"children":[
{
"type":"p",
"hlId":"2943dc",
"children":[
"Cystic fibrosis (CF) is an autosomal recessive disease affecting the CF transmembrane conductance regulator (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CFTR"
]
},
") gene. It is diagnosed in approximately 1 of 2000 to 3000 live births with a predilection for disease in those of European descent. The most common genetic variant resulting in disease is ΔF508, but there are at least 1500 other genetic mutations. The pathogenesis for clinical manifestations of CF remains incompletely understood; however, the abnormal homozygous ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CFTR"
]
},
" genotype results in abnormally thick secretions that are difficult to clear. There is an increased concentration of chloride in sweat gland secretions, and sweat chloride testing is a primary diagnostic tool for CF. The changes in respiratory secretions lead to bacterial colonization of airways and chronic bacterial infection, resulting in chronic inflammation and, ultimately, bronchiectasis. Further tissue destruction results from insufficient lung antiproteases to counteract the effect of elastase released from neutrophils. This ongoing inflammatory process also results in large amounts of free DNA and matrix protein deposition within areas of tissue destruction, which further drives increased viscosity of lung secretions."
]
},
{
"type":"p",
"hlId":"bdce1e",
"children":[
"Thickened secretions in the gastrointestinal tract impair flow of bile and pancreatic secretions, leading to pancreatic exocrine and endocrine deficiency, liver disease, and the development of malabsorption and maldigestion. The secretions increase the risk for bowel obstruction (distal ileal obstructive syndrome, intussusception, and rectal prolapse). As a consequence, individuals with CF often present with malnutrition and weight loss."
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_4_1",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"0860c7",
"children":[
"Most patients with CF are diagnosed as children. Adults diagnosed with CF most often present with pulmonary or gastrointestinal symptoms. Pulmonary manifestations often include chronic productive cough, recurrent sinusitis, and recurrent pulmonary infections requiring several courses of antibiotics. For those with gastrointestinal symptoms, loose and frequent stools with abdominal pain are the most common. Pancreatic insufficiency (either endocrine or exocrine) may occur but is less common. Chronic, persistent pulmonary or gastrointestinal symptoms requiring repetitive treatment should raise suspicion for CF. Radiographic findings include hyperinflation followed by bronchiectasis and cyst formation with disease progression, often beginning in the upper lobes."
]
},
{
"type":"p",
"hlId":"9fa81a",
"children":[
"Often the greatest challenge in diagnosing CF is failing to include it in the differential diagnosis. A family history of CF can be quite helpful in this regard. Sweat chloride testing is the initial test for CF, although it is less sensitive in adults. Abnormal results on repeat testing are diagnostic of CF. Genetic testing confirms the diagnosis and helps with prognosis. A negative sweat chloride test in an adult patient does not rule out disease. Therefore, if the clinical suspicion remains high after negative repeat sweat chloride testing, consideration for referral to a center with expertise in CF or genetic testing is appropriate."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"4e3c0b",
"children":[
"Adults diagnosed with cystic fibrosis most often present with pulmonary or gastrointestinal symptoms; pulmonary manifestations often include chronic productive cough, recurrent sinusitis, and recurrent pulmonary infections requiring several courses of antibiotics."
]
},
{
"type":"keypoint",
"hlId":"07d42a",
"children":[
"A negative sweat chloride test in a patient who presents as an adult should not rule out cystic fibrosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_4_2",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"2a9161",
"children":[
"The pillars of CF management are airway clearance, antibiotic therapy, nutritional support, and psychosocial support. The primary objectives of CF treatment are maintaining lung health and controlling/minimizing the effect of CF-affected organ disease. The Cystic Fibrosis Foundation practice guidelines recommend use of chronic medications to improve lung function and reduce exacerbations. These medications include mucolytics, hydrating agents, inhaled antibiotics, oral macrolide antibiotics, and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CFTR"
]
},
" potentiators. The treatment of CF lung disease is experiencing a period of rapid evolution, and management involves a multidisciplinary approach best provided at a CF care center."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s2_5",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Beasley R, Holliday M, Reddel HK, et al; Novel START Study Team. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020-2030. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31112386",
"target":"_blank"
},
"children":[
"PMID: 31112386"
]
},
" doi:10.1056/NEJMoa1901963"
]
},
{
"type":"reference",
"children":[
"Cloutier MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020;324:2301-2317. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33270095",
"target":"_blank"
},
"children":[
"PMID: 33270095"
]
},
" doi:10.1001/jama.2020.21974"
]
},
{
"type":"reference",
"children":[
"Global Initiative for Asthma. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://ginasthma.org/gina-reports/Global",
"target":"_blank"
},
"children":[
"https://ginasthma.org/gina-reports/Global"
]
},
" strategy for asthma management and prevention, 2021. Accessed May 5, 2021."
]
},
{
"type":"reference",
"children":[
"Global Initiative for Chronic Obstructive Lung Disease. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://goldcopd.org/gold-reports/Global",
"target":"_blank"
},
"children":[
"https://goldcopd.org/gold-reports/Global"
]
},
" strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Accessed September 27, 2020."
]
},
{
"type":"reference",
"children":[
"Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. BMJ Open Respir Res. 2018;5:e000348. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30687502",
"target":"_blank"
},
"children":[
"PMID: 30687502"
]
},
" doi:10.1136/bmjresp-2018-000348"
]
},
{
"type":"reference",
"children":[
"Khatri SB, Iaccarino JM, Barochia A, et al; American Thoracic Society Assembly on Allergy, Immunology, and Inflammation. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021;204:e97-e109. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34779751",
"target":"_blank"
},
"children":[
"PMID: 34779751"
]
},
" doi:10.1164/rccm.202109-2093ST"
]
},
{
"type":"reference",
"children":[
"Murthy N, Wodi AP, Bernstein H, et al; Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2022. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M22-0036",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2022;175:432-443. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35175828",
"target":"_blank"
},
"children":[
"PMID: 35175828"
]
}
]
},
{
"type":"reference",
"children":[
"Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and management of asthma exacerbations. Am J Respir Crit Care Med. 2019;199:423-432. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30562041",
"target":"_blank"
},
"children":[
"PMID: 30562041"
]
},
" doi:10.1164/rccm.201810-1931CIRusznak M1, Peebles RS. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018 Dec 6;379(23):2280-2281."
]
},
{
"type":"reference",
"children":[
"Skloot GS, Busse PJ, Braman SS, et al; ATS ad hoc Committee on Asthma in the Elderly. An official American Thoracic Society Workshop report: evaluation and management of asthma in the elderly. Ann Am Thorac Soc. 2016;13:2064-2077. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27831798",
"target":"_blank"
},
"children":[
"PMID: 27831798"
]
}
]
},
{
"type":"reference",
"children":[
"Siu AL, Bibbins-Domingo K, Grossman DC, et al; US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US preventive services task force recommendation statement. JAMA. 2016;315:1372-7. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27046365",
"target":"_blank"
},
"children":[
"PMID: 27046365"
]
},
" doi:10.1001/jama.2016.2638"
]
},
{
"type":"reference",
"children":[
"Walshaw MJ. Cystic fibrosis: diagnosis and management-NICE guideline 78. Paediatr Respir Rev. 2019;31:12-14. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30962150",
"target":"_blank"
},
"children":[
"PMID: 30962150"
]
},
" doi:10.1016/j.prrv.2019.02.006"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_pm_t05":{
"id":"mk19_b_pm_t05",
"number":5,
"bookId":"pm",
"title":{
"__html":"Common Asthma Comorbidities"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"25fa43",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 5. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t05"
}
]
},
"Common Asthma Comorbidities"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15edea",
"class":"col hd l",
"children":[
"Comorbidity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd2968",
"class":"col hd l",
"children":[
"Symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72050b",
"class":"col hd l",
"children":[
"Diagnosis and Treatment"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b9383",
"class":"cell txt l",
"children":[
"Gastroesophageal reflux disease (GERD)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2338b4",
"class":"cell txt l",
"children":[
"Frequently coexists in patients with asthma"
]
},
" ",
{
"type":"p",
"hlId":"7f39dd",
"class":"cell txt l",
"children":[
"May be an independent cause of respiratory symptoms such as cough and chest pain"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"708c6b",
"class":"cell txt l",
"children":[
"Empiric trial of a proton pump inhibitor for 2 months"
]
},
" ",
{
"type":"p",
"hlId":"7e5345",
"class":"cell txt l",
"children":[
"Consider further testing such as endoscopy and 24-hour esophageal pH monitoring if symptoms do not improve"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a8a5c1",
"class":"cell txt l",
"children":[
"Sinus disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47e4ec",
"class":"cell txt l",
"children":[
"Allergic rhinitis: rhinorrhea, nasal obstruction, itching, and sneezing; symptoms can be seasonal, intermittent, or perennial (usually caused by persistent exposure to indoor allergens such as dust mites)"
]
},
" ",
{
"type":"p",
"hlId":"048c11",
"class":"cell txt l",
"children":[
"Chronic rhinosinusitis: additional symptoms of facial pain, sinus pressure, and sometimes anosmia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc0e97",
"class":"cell txt l",
"children":[
"Intranasal glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"701ebe",
"class":"cell txt l",
"children":[
"For severe cases, consider adding:"
]
},
" ",
{
"type":"p",
"hlId":"9580be",
"class":"cell txt li",
"children":[
"Intranasal H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"-antihistamines"
]
},
" ",
{
"type":"p",
"hlId":"8b70ba",
"class":"cell txt li",
"children":[
"Oral antileukotrienes"
]
},
" ",
{
"type":"p",
"hlId":"02d706",
"class":"cell txt li",
"children":[
"Oral glucocorticoids"
]
},
" ",
{
"type":"p",
"hlId":"d39191",
"class":"cell txt li",
"children":[
"Immunotherapy"
]
},
" ",
{
"type":"p",
"hlId":"eb1fa7",
"class":"cell txt li",
"children":[
"Biologic targeting IgE or eosinophils"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"881ee6",
"class":"cell txt l",
"children":[
"Obstructive sleep apnea",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"702c24",
"class":"cell txt l",
"children":[
"Snoring, excessive daytime sleepiness, and witnessed apneas"
]
},
" ",
{
"type":"p",
"hlId":"6c2b0a",
"class":"cell txt l",
"children":[
"More common in patients with asthma than those without asthma"
]
},
" ",
{
"type":"p",
"hlId":"3b9ad1",
"class":"cell txt l",
"children":[
"Worsens asthma control, increases asthma-related health care use, and reduces quality of life"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"747440",
"class":"cell txt l",
"children":[
"Confirm with polysomnography or home sleep testing"
]
},
" ",
{
"type":"p",
"hlId":"ff73a3",
"class":"cell txt l",
"children":[
"Positive airway pressure: improves asthma symptoms, quality of life, bronchodilator use, and peak flow rates"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb41ee",
"class":"cell txt l",
"children":[
"Vocal cord dysfunction (VCD)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f319b",
"class":"cell txt l",
"children":[
"Inspiratory breathlessness, with throat tightness or voice dysfunction during attacks"
]
},
" ",
{
"type":"p",
"hlId":"945ba6",
"class":"cell txt l",
"children":[
"Caused by paradoxical adduction of the vocal cords during inspiration, causing functional upper airway obstruction"
]
},
" ",
{
"type":"p",
"hlId":"52ba9b",
"class":"cell txt l",
"children":[
"Often triggered by exercise, exposure to fumes or irritants, and stress"
]
},
" ",
{
"type":"p",
"hlId":"c748eb",
"class":"cell txt l",
"children":[
"May mimic or coexist with asthma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"207c58",
"class":"cell txt l",
"children":[
"Laryngoscopy demonstrating paradoxical vocal cord adduction during a symptomatic episode"
]
},
" ",
{
"type":"p",
"hlId":"20dce8",
"class":"cell txt l",
"children":[
"Patients often asymptomatic when evaluated or unable to tolerate laryngoscopy during an acute episode"
]
},
" ",
{
"type":"p",
"hlId":"e8b311",
"class":"cell txt l",
"children":[
"Trial of treatment with speech therapy"
]
},
" ",
{
"type":"p",
"hlId":"3ea3a1",
"class":"cell txt l",
"children":[
"Also address factors known to worsen VCD (GERD, postnasal drip)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f01d8",
"class":"cell txt l",
"children":[
"Obesity",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd2968",
"class":"cell txt l",
"children":[
"Symptoms"
]
},
" ",
{
"type":"p",
"hlId":"59bced",
"class":"cell txt l",
"children":[
"Dyspnea, wheezing"
]
},
" ",
{
"type":"p",
"hlId":"d6c3b3",
"class":"cell txt l",
"children":[
"Higher prevalence of asthma with poorer symptom control compared with patients with asthma and normal BMI; and not as responsive to standard controller therapies"
]
},
" ",
{
"type":"p",
"hlId":"1002fb",
"class":"cell txt l",
"children":[
"May confound asthma diagnosis because of overlapping symptoms of breathlessness and exertional wheezing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96ea59",
"class":"cell txt l",
"children":[
"BMI measurement and objective documentation of reversible airway obstruction in all patients undergoing asthma evaluation"
]
},
" ",
{
"type":"p",
"hlId":"e1a427",
"class":"cell txt l",
"children":[
"Weight loss: improves asthma control and lung function"
]
},
" ",
{
"type":"p",
"hlId":"99361a",
"class":"cell txt l",
"children":[
"Bariatric surgery: greater amounts of weight loss correlate with better outcomes"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"See ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s1_2_1",
"children":[
"MKSAP 19 Gastroenterology and Hepatology: Disorders of the Esophagus"
]
},
" section."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"See ",
{
"type":"cross-reference",
"target":"mk19_b_pm_s8_3",
"children":[
"Sleep Medicine"
]
},
" section."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s5",
"children":[
"MKSAP 19 General Internal Medicine 2: Obesity"
]
},
" section."
]
]
},
"mk19_b_pm_t06":{
"id":"mk19_b_pm_t06",
"number":6,
"bookId":"pm",
"title":{
"__html":"Asthma Medications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8a3f61",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 6. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t06"
}
]
},
"Asthma Medications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9c88a",
"class":"col hd l",
"children":[
"Formulations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8bc11",
"class":"col hd l",
"children":[
"Adverse Effects"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1b151",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Short-Acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Agonists"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88bd07",
"class":"cell txt li",
"children":[
"Albuterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66ce3f",
"class":"cell txt l",
"children":[
"HFA-MDI, nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00f2ad",
"class":"cell txt l",
"children":[
"Tachycardia and hypokalemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"923bd4",
"class":"cell txt li",
"children":[
"Levalbuterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66ce3f",
"class":"cell txt l",
"children":[
"HFA-MDI, nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f310af",
"class":"cell txt l",
"children":[
"Should not be used as monotherapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"901593",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Short-acting Anticholinergics (Muscarinic Antagonists)"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2ea77",
"class":"cell txt li",
"children":[
"Ipratropium bromide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66ce3f",
"class":"cell txt l",
"children":[
"HFA-MDI, nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"225e4d",
"class":"cell txt l",
"children":[
"Dry mouth, tachycardia, acute narrow-angle glaucoma (rare)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6bca3c",
"class":"cell txt li",
"children":[
"Albuterol/ipratropium bromide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66ce3f",
"class":"cell txt l",
"children":[
"HFA-MDI, nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"569f09",
"class":"cell txt l",
"children":[
"Same and combined effects of both drug classes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"f44ea6",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Long-Acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Agonists"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f528db",
"class":"cell txt li",
"children":[
"Formoterol",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50cc99",
"class":"cell txt l",
"children":[
"Tremor, tachycardia; black box warning for use of long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist monotherapy in asthma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"280eec",
"class":"cell txt li",
"children":[
"Salmeterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc140b",
"class":"cell txt li",
"children":[
"Arformoterol",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f91440",
"class":"cell txt l",
"children":[
"Nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c1a49",
"class":"cell txt li",
"children":[
"Formoterol fumarate",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f91440",
"class":"cell txt l",
"children":[
"Nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6dad9",
"class":"cell txt li",
"children":[
"Olodaterol",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bc3835",
"class":"cell txt l",
"children":[
"SMI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b567b0",
"class":"cell txt li",
"children":[
"Indacaterol maleate",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"d833a2",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Long-acting Muscarinic Antagonists (Anticholinergics)"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"17b375",
"class":"cell txt li",
"children":[
"Tiotropium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ea006",
"class":"cell txt l",
"children":[
"DPI, SMI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78a40a",
"class":"cell txt l",
"children":[
"Dry mouth, tachycardia, urinary retention, acute narrow-angle glaucoma (rare)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e0dfa",
"class":"cell txt li",
"children":[
"Aclidinium bromide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d595e",
"class":"cell txt li",
"children":[
"Umeclidinium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e10213",
"class":"cell txt li",
"children":[
"Glycopyrrolate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"85ef3f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Inhaled Glucocorticoids"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16ab45",
"class":"cell txt li",
"children":[
"Beclomethasone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa7190",
"class":"cell txt l",
"children":[
"HFA-MDI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d732aa",
"class":"cell txt l",
"children":[
"Dysphonia, xerostomia, oral candidiasis, bruising, pneumonia; low incidence of oral glucocorticoid adverse effects"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34e224",
"class":"cell txt li",
"children":[
"Budesonide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3bdc5",
"class":"cell txt l",
"children":[
"DPI, nebulizer solution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"042c69",
"class":"cell txt li",
"children":[
"Fluticasone propionate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a28cf",
"class":"cell txt l",
"children":[
"HFA, DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"581e1f",
"class":"cell txt li",
"children":[
"Fluticasone furoate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0677a1",
"class":"cell txt li",
"children":[
"Mometasone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d9987",
"class":"cell txt li",
"children":[
"Ciclesonide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa7190",
"class":"cell txt l",
"children":[
"HFA-MDI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"227255",
"class":"cell txt li",
"children":[
"Flunisolide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa7190",
"class":"cell txt l",
"children":[
"HFA-MDI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"663f34",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Inhaled Glucocorticoids and Long-Acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Agonists"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9046cb",
"class":"cell txt li",
"children":[
"Budesonide and formoterol",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5245e6",
"class":"cell txt l",
"children":[
"HFA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cb7b1",
"class":"cell txt l",
"children":[
"Same as combined effects of both drug classes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe8c23",
"class":"cell txt li",
"children":[
"Fluticasone and salmeterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a28cf",
"class":"cell txt l",
"children":[
"HFA, DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8c868",
"class":"cell txt li",
"children":[
"Mometasone furoate and formoterol fumarate",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5245e6",
"class":"cell txt l",
"children":[
"HFA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f22c0e",
"class":"cell txt li",
"children":[
"Fluticasone furoate and vilanterol",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a76534",
"class":"cell txt l",
"children":[
"DPI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"63f3a2",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Oral Glucocorticoids"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c03f2",
"class":"cell txt li",
"children":[
"Prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1af34",
"class":"cell txt l",
"children":[
"Tablet, liquid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"218cc5",
"class":"cell txt l",
"children":[
"Bruising, adrenal suppression, osteoporosis, glaucoma, diabetes mellitus, opportunistic infection, insomnia, cataracts, hypertension, weight gain, myopathy, acne"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6e8a0",
"class":"cell txt li",
"children":[
"Prednisolone"
]
},
" ",
{
"type":"p",
"hlId":"3a8f74",
"class":"cell txt li",
"children":[
"Methylprednisolone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1af34",
"class":"cell txt l",
"children":[
"Tablet, liquid"
]
},
" ",
{
"type":"p",
"hlId":"584212",
"class":"cell txt l",
"children":[
"IV infusion, tablet"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"2705d7",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Leukotriene-Modifying Agents"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d05068",
"class":"cell txt li",
"children":[
"Montelukast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36384a",
"class":"cell txt l",
"children":[
"Tablet"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c010c",
"class":"cell txt l",
"children":[
"Headache; rarely liver disease; neuropsychiatric events, including suicidal thoughts and actions"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbc26f",
"class":"cell txt li",
"children":[
"Zafirlukast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36384a",
"class":"cell txt l",
"children":[
"Tablet"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5be5ce",
"class":"cell txt li",
"children":[
"Zileuton (5-lipoxygenase inhibitor)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36384a",
"class":"cell txt l",
"children":[
"Tablet"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"da8152",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Biologic Agents"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66cbf7",
"class":"cell txt li",
"children":[
"Omalizumab (anti-IgE)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1660b5",
"class":"cell txt l",
"children":[
"Subcutaneous injection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e77cf",
"class":"cell txt l",
"children":[
"Anaphylaxis, increased risk for malignancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b5f98",
"class":"cell txt li",
"children":[
"Mepolizumab (anti-IL-5)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1660b5",
"class":"cell txt l",
"children":[
"Subcutaneous injection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"221f1c",
"class":"cell txt li",
"children":[
"Reslizumab (anti-IL-5)"
]
},
" ",
{
"type":"p",
"hlId":"ea9333",
"class":"cell txt li",
"children":[
"Benralizumab (anti-IL-5)"
]
},
" ",
{
"type":"p",
"hlId":"011fd0",
"class":"cell txt li",
"children":[
"Dupilumab (anti-IL-4 and IL-13)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eae263",
"class":"cell txt l",
"children":[
"IV infusion"
]
},
" ",
{
"type":"p",
"hlId":"1660b5",
"class":"cell txt l",
"children":[
"Subcutaneous injection"
]
},
" ",
{
"type":"p",
"hlId":"1660b5",
"class":"cell txt l",
"children":[
"Subcutaneous injection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"202250",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Other"
]
},
" "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47cfd8",
"class":"cell txt li",
"children":[
"Theophylline"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab5677",
"class":"cell txt l",
"children":[
"Tablet, capsule, liquid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e72a6c",
"class":"cell txt l",
"children":[
"Tachycardia, nausea, overdose can be fatal"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DPI = dry powder inhaler; HFA = hydrofluoroalkane; IL = interleukin; IV = intravenous; MDI = metered dose inhaler; SMI = soft mist inhaler."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Relief of acute bronchospasm is an off-label indication for this medication."
]
]
},
"mk19_b_pm_t07":{
"id":"mk19_b_pm_t07",
"number":7,
"bookId":"pm",
"title":{
"__html":"Severe Asthma Exacerbation Risk Factors and Signs"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"943f51",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t07"
}
]
},
"Severe Asthma Exacerbation Risk Factors and Signs"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c50bad",
"class":"col hd l",
"children":[
"Risk Factors for Asthma-Related Death"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b99ad4",
"class":"cell txt l",
"children":[
"History of near-fatal asthma attack or intubation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2257df",
"class":"cell txt l",
"children":[
"Emergency department or hospital visit in the last 12 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b8041",
"class":"cell txt l",
"children":[
"Poor asthma medication adherence or not using inhaled glucocorticoid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"517e88",
"class":"cell txt l",
"children":[
"Current or recent treatment with oral glucocorticoid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a0b22",
"class":"cell txt l",
"children":[
"Psychosocial stressors or psychiatric disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c428f5",
"class":"cell txt l",
"children":[
"Food allergy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a1cfd",
"class":"cell txt l",
"children":[
"Overuse of short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5fe7cd",
"class":"col hd l",
"children":[
"Signs of a Severe Asthma Exacerbation"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9ac3d7",
"class":"cell txt l",
"children":[
"Unable to speak in full sentences"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9558af",
"class":"cell txt l",
"children":[
"Use of accessory muscles of respiration"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"128f06",
"class":"cell txt l",
"children":[
"Respiration rate >30/min, heart rate >120/min"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56b533",
"class":"cell txt l",
"children":[
"SpO",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" <90% on ambient air"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"959af2",
"class":"cell txt l",
"children":[
"Agitation, confusion, or drowsiness"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"SpO",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
" = oxygen saturation as measured by pulse oximetry."
]
]
},
"mk19_b_pm_t08":{
"id":"mk19_b_pm_t08",
"number":8,
"bookId":"pm",
"title":{
"__html":"Modified Medical Research Council Dyspnea Scale"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"cb06aa",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t08"
}
]
},
"Modified Medical Research Council Dyspnea Scale"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5dd135",
"class":"col hd l",
"children":[
"Score"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c23f6c",
"class":"col hd l",
"children":[
"Description of Dyspnea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"007cc9",
"class":"col hd l",
"children":[
"Severity"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f097c",
"class":"cell txt l",
"children":[
"I get breathless only with strenuous exercise."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca3f27",
"class":"cell txt l",
"children":[
"I get short of breath when hurrying on level ground or walking up a slight hill."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dce379",
"class":"cell txt l",
"children":[
"On level ground, I walk slower than other people my age because of breathlessness, or I have to stop for breath when walking at my own pace."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad2f80",
"class":"cell txt l",
"children":[
"I stop for breath after walking approximately 100 yards or after a few minutes on level ground."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6811a",
"class":"cell txt l",
"children":[
"I am too breathless to leave the house or breathless when dressing."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e0040",
"class":"cell txt l",
"children":[
"Very severe"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Based on the 1959 MRC Breathlessness Scale, as modified and published in Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report; 28. Accessed September 27, 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://goldcopd.org/gold-reports/",
"target":"_blank"
},
"children":[
"https://goldcopd.org/gold-reports/"
]
},
". Used with the permission of the Medical Research Council."
]
]
},
"mk19_b_pm_t09":{
"id":"mk19_b_pm_t09",
"number":9,
"bookId":"pm",
"title":{
"__html":"BODE Index to Estimate Prognosis of COPD"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a67ffa",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t09"
}
]
},
"BODE Index to Estimate Prognosis of COPD"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83f499",
"class":"col hd l",
"children":[
"Parameter"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f96f7",
"class":"col hd l",
"children":[
"Points Assigned"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c31b3",
"class":"col hd l",
"children":[
"BMI"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee58f9",
"class":"cell txt l",
"children":[
">21"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0fb49f",
"class":"cell txt l",
"children":[
"≤21"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"973014",
"class":"col hd l",
"children":[
"Obstruction of Airflow: FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" (Postbronchodilator Percentage Predicted)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e23714",
"class":"cell txt l",
"children":[
">65%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8f4c5",
"class":"cell txt l",
"children":[
"50%-64%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"158dd4",
"class":"cell txt l",
"children":[
"36%-49%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86767a",
"class":"cell txt l",
"children":[
"<35%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"73052e",
"class":"col hd l",
"children":[
"Dyspnea: mMRC Score"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2eb28",
"class":"cell txt l",
"children":[
"0-1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d47d3",
"class":"col hd l",
"children":[
"Exercise Capacity: 6-Minute Walking Distance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79c2d8",
"class":"cell txt l",
"children":[
"≥350 m"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d486ee",
"class":"cell txt l",
"children":[
"250-349 m"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"955b1b",
"class":"cell txt l",
"children":[
"150-249 m"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c81e72",
"class":"cell txt l",
"children":[
"2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"990419",
"class":"cell txt l",
"children":[
"≤149 m"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"BODE = body mass, airflow obstruction, dyspnea, and exercise; mMRC = Modified British Medical Research Council dyspnea scale. Approximate 4-year survival: 0-2 points: 80%; 3-4 points: 67%; 5-6 points: 57%; 7-10 points: 18%."
],
[
"From Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1007. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/14999112",
"target":"_blank"
},
"children":[
"PMID: 14999112"
]
},
". Copyright © 2004 Massachusetts Medical Society. Reproduced with permission from the Massachusetts Medical Society."
]
]
},
"mk19_b_pm_t10":{
"id":"mk19_b_pm_t10",
"number":10,
"bookId":"pm",
"title":{
"__html":"Classification of Airflow Limitation Severity in COPD by Spirometry<sup>a,b</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3504a4",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t10"
}
]
},
"Classification of Airflow Limitation Severity in COPD by Spirometry",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3adbdb",
"class":"col hd l",
"children":[
"Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"007cc9",
"class":"col hd l",
"children":[
"Severity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"094035",
"class":"col hd l",
"children":[
"Spirometry"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b16c4",
"class":"cell txt l",
"children":[
"GOLD 1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5be24b",
"class":"cell txt l",
"children":[
"FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" ≥80% predicted"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd87bb",
"class":"cell txt l",
"children":[
"GOLD 2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2777ac",
"class":"cell txt l",
"children":[
"50% ≤ FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" < 80% predicted"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f23275",
"class":"cell txt l",
"children":[
"GOLD 3"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9d538",
"class":"cell txt l",
"children":[
"30% ≤ FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" < 50% predicted"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f0f77",
"class":"cell txt l",
"children":[
"GOLD 4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e0040",
"class":"cell txt l",
"children":[
"Very severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67201e",
"class":"cell txt l",
"children":[
"FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" <30% predicted"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GOLD = Global Initiative for Chronic Obstructive Lung Disease."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"In patients with FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"/FVC less than 0.7."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Based on postbronchodilator FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
"."
],
[
"Reproduced with permission, from Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report; 27. Copyright 2020, Global Initiative for Chronic Obstructive Lung Disease, available from ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.goldcopd.org",
"target":"_blank"
},
"children":[
"www.goldcopd.org"
]
},
", published in Fontana, WI, USA."
]
]
},
"mk19_b_pm_t11":{
"id":"mk19_b_pm_t11",
"number":11,
"bookId":"pm",
"title":{
"__html":"GOLD Model for Classifying Severity of Disease in COPD<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1fa9a2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t11"
}
]
},
"GOLD Model for Classifying Severity of Disease in COPD",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c6997",
"class":"col hd l",
"children":[
"Patient Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93932b",
"class":"col hd l",
"children":[
"Characteristics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa3170",
"class":"col hd l",
"children":[
"Exacerbations Per Year"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2e83d",
"class":"col hd l",
"children":[
"CAT Score"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15cc42",
"class":"col hd l",
"children":[
"mMRC Score"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fc562",
"class":"cell txt l",
"children":[
"A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a6144",
"class":"cell txt l",
"children":[
"Low risk, fewer symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fe111",
"class":"cell txt l",
"children":[
"≤1, no hospitalization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95acc5",
"class":"cell txt l",
"children":[
"<10"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2eb28",
"class":"cell txt l",
"children":[
"0-1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d5ed6",
"class":"cell txt l",
"children":[
"B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c4643",
"class":"cell txt l",
"children":[
"Low risk, more symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fe111",
"class":"cell txt l",
"children":[
"≤1, no hospitalization"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d99ea",
"class":"cell txt l",
"children":[
"≥10"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"357080",
"class":"cell txt l",
"children":[
"≥2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06fa4f",
"class":"cell txt l",
"children":[
"High risk, fewer symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7a37c",
"class":"cell txt l",
"children":[
"≥2 or ≥1 with hospital admission"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95acc5",
"class":"cell txt l",
"children":[
"<10"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2eb28",
"class":"cell txt l",
"children":[
"0-1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f623e7",
"class":"cell txt l",
"children":[
"D"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cea46",
"class":"cell txt l",
"children":[
"High risk, more symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7a37c",
"class":"cell txt l",
"children":[
"≥2 or ≥1 with hospital admission"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d99ea",
"class":"cell txt l",
"children":[
"≥10"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"357080",
"class":"cell txt l",
"children":[
"≥2"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CAT = COPD Assessment Test; GOLD = Global Initiative for Chronic Obstructive Lung Disease; mMRC = Modified Medical Research Council dyspnea scale."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"See Table 10 for definitions of spirometric classifications."
],
[
"Information from Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Accessed September 27, 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://goldcopd.org/gold-reports/",
"target":"_blank"
},
"children":[
"https://goldcopd.org/gold-reports/"
]
}
]
]
},
"mk19_b_pm_t12":{
"id":"mk19_b_pm_t12",
"number":12,
"bookId":"pm",
"title":{
"__html":"Recommended Pharmacologic Management of COPD by GOLD Classification"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f66a96",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t12"
}
]
},
"Recommended Pharmacologic Management of COPD by GOLD Classification"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a59220",
"class":"col hd l",
"children":[
"Patient Group"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f05b9",
"class":"col hd l",
"children":[
"Recommended Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"034a47",
"class":"col hd l",
"children":[
"Alternative Therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7db1b",
"class":"col hd l",
"children":[
"Other Considerations"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fc562",
"class":"cell txt l",
"children":[
"A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"848c74",
"class":"cell txt l",
"children":[
"Short-acting bronchodilator ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"c036fb",
"class":"cell txt l",
"children":[
"Long-acting bronchodilator"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9f43c",
"class":"cell txt l",
"children":[
"Evaluate effect of therapy and continue, stop, or try alternative bronchodilator as appropriate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2abf01",
"class":"cell txt l",
"children":[
"All patients in group A should receive bronchodilator therapy based on its effect on dyspnea; therapy should be continued if symptomatic benefit is documented."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d5ed6",
"class":"cell txt l",
"children":[
"B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73c36c",
"class":"cell txt l",
"children":[
"Long-acting bronchodilator (LABA or LAMA) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"a022df",
"class":"cell txt l",
"children":[
"Combination therapy with two bronchodilators may be considered for patients with severe dyspnea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"351804",
"class":"cell txt l",
"children":[
"If symptoms persist after one long-acting bronchodilator, try combined therapy with LABA and LAMA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3b14d",
"class":"cell txt l",
"children":[
"Long-acting inhaled bronchodilators are superior to short-acting bronchodilators received as needed."
]
},
" ",
{
"type":"p",
"hlId":"5bec70",
"class":"cell txt l",
"children":[
"There is no evidence to support use of one class of long-acting bronchodilators over another for initial relief of symptoms for patients in group B. In the individual patient, the choice should depend on the patient's perception of symptom relief."
]
},
" ",
{
"type":"p",
"hlId":"d1f832",
"class":"cell txt l",
"children":[
"Patients in group B are likely to have comorbidities that affect symptoms and prognosis, and these should be investigated."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d61f8",
"class":"cell txt l",
"children":[
"C"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56b35f",
"class":"cell txt l",
"children":[
"LAMA; if further exacerbations, LAMA and LABA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b03ff7",
"class":"cell txt l",
"children":[
"LABA and inhaled glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94a9f5",
"class":"cell txt l",
"children":[
"LABA and LAMA is preferred to LABA and inhaled glucocorticoids because inhaled glucocorticoids increase the risk of developing pneumonia in some patients."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f623e7",
"class":"cell txt l",
"children":[
"D"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ffd45",
"class":"cell txt l",
"children":[
"LAMA or"
]
},
" ",
{
"type":"p",
"hlId":"fa7d0a",
"class":"cell txt l",
"children":[
"LAMA and LABA",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"334474",
"class":"cell txt l",
"children":[
"Inhaled glucocorticoids and LABA",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e408fd",
"class":"cell txt l",
"children":[
"If exacerbations continue, consider:"
]
},
" ",
{
"type":"p",
"hlId":"8c310e",
"class":"cell txt l",
"children":[
"Roflumilast (patients with an FEV",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1"
]
},
" <50% of predicted and chronic bronchitis, particularly if they have experienced at least one hospitalization for an exacerbation in the previous year) ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
},
" ",
{
"type":"p",
"hlId":"6b7e6b",
"class":"cell txt l",
"children":[
"Macrolide therapy (the best available evidence exists for the use of azithromycin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"729b7f",
"class":"cell txt l",
"children":[
"Initial therapy with LABA and inhaled glucocorticoids may be appropriate in some patients, including those with a history or findings suggestive of asthma."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"GOLD = Global Initiative for Chronic Obstructive Lung Disease; LABA = long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist; LAMA = long-acting muscarinic agent."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Consider if highly symptomatic."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Consider if eosinophils >300/μL (0.30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
],
[
"Information from Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. Accessed September 27, 2020. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://goldcopd.org/gold-reports/",
"target":"_blank"
},
"children":[
"https://goldcopd.org/gold-reports/"
]
}
]
]
},
"mk19_b_pm_t13":{
"id":"mk19_b_pm_t13",
"number":13,
"bookId":"pm",
"title":{
"__html":"Drugs Used in the Treatment of COPD"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"33bf24",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 13. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t13"
}
]
},
"Drugs Used in the Treatment of COPD"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8bc11",
"class":"col hd l",
"children":[
"Adverse Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"8313e7",
"class":"col hd l",
"children":[
"Bronchodilators"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55e22b",
"class":"cell txt l",
"children":[
"Inhaled short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists (albuterol, fenoterol, levalbuterol, metaproterenol, pirbuterol, terbutaline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9166cc",
"class":"cell txt l",
"children":[
"Tachycardia and hypokalemia (usually dose dependent), but generally well tolerated by most patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d034db",
"class":"cell txt l",
"children":[
"Generally used as needed for mild disease with few symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"59f522",
"class":"cell txt l",
"children":[
"Inhaled short-acting anticholinergic agents (ipratropium)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f602f0",
"class":"cell txt l",
"children":[
"Dry mouth, mydriasis on contact with eye, tachycardia, tremors; rarely acute narrow-angle glaucoma; this drug class has been shown to be safe in a wide range of doses and clinical settings"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"940997",
"class":"cell txt l",
"children":[
"Generally used as needed for mild disease with few symptoms; avoid using both short- and long-acting anticholinergics"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a594a4",
"class":"cell txt l",
"children":[
"Inhaled long-acting anticholinergic agents (tiotropium, aclidinium, umeclidinium, glycopyrrolate)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16b1ee",
"class":"cell txt l",
"children":[
"Dry mouth, mydriasis on contact with eye, tachycardia, tremors; rarely acute narrow-angle glaucoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e8739",
"class":"cell txt l",
"children":[
"Not to be used with ipratropium; use when short-acting bronchodilators provide insufficient control of symptoms"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f985b",
"class":"cell txt l",
"children":[
"Inhaled long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists (salmeterol, formoterol, arformoterol, indacaterol, olodaterol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebba80",
"class":"cell txt l",
"children":[
"Sympathomimetic symptoms such as tremor and tachycardia; overdose can be fatal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee856f",
"class":"cell txt l",
"children":[
"Use as maintenance therapy when short-acting bronchodilators provide insufficient control of symptoms; not intended to be used for treatment of exacerbations of COPD or acute bronchospasm"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb65f5",
"class":"cell txt l",
"children":[
"Methylxanthines (theophylline, aminophylline; sustained and short-acting)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f4524",
"class":"cell txt l",
"children":[
"Tachycardia, nausea, vomiting, and disturbed sleep; narrow therapeutic index; overdose can be fatal with seizures and arrhythmias"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18db6a",
"class":"cell txt l",
"children":[
"Used as maintenance therapy; generally used only after long-acting bronchodilator treatment to provide additional symptomatic relief of exacerbations; may also improve respiratory muscle function"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc8bf5",
"class":"cell txt l",
"children":[
"Oral β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonists (albuterol, metaproterenol, terbutaline)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd85bf",
"class":"cell txt l",
"children":[
"Sympathomimetic symptoms such as tremor and tachycardia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2ca0c",
"class":"cell txt l",
"children":[
"Used as maintenance therapy; rarely used because of adverse effects but may be beneficial for patients who cannot use inhalers"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"483a50",
"class":"col hd l",
"children":[
"Oral Phosophodiesterase-4 Inhibitor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"41b167",
"class":"cell txt l",
"children":[
"Roflumilast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"840889",
"class":"cell txt l",
"children":[
"Diarrhea, nausea, backache, decreased appetite, dizziness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c173e",
"class":"cell txt l",
"children":[
"Used to reduce risk for exacerbations in patients with severe COPD with chronic bronchitis and history of exacerbations; roflumilast should not be used with methylxanthines because of potential toxicity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d19ff",
"class":"col hd l",
"children":[
"Anti-Inflammatory Agents"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea96e9",
"class":"cell txt l",
"children":[
"Inhaled glucocorticoids (fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, flunisolide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e29513",
"class":"cell txt l",
"children":[
"Dysphonia, skin bruising, oral candidiasis; rarely adverse effects of oral glucocorticoids (see below)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c6025",
"class":"cell txt l",
"children":[
"Most effective in patients with a history of frequent exacerbations and when used in conjunction with long-acting bronchodilators"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96a435",
"class":"cell txt l",
"children":[
"Oral glucocorticoids (prednisone, prednisolone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"207fda",
"class":"cell txt l",
"children":[
"Skin bruising, adrenal suppression, glaucoma, osteoporosis, diabetes mellitus, systemic hypertension, pneumonia, cataracts, opportunistic infection, insomnia, mood disturbance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"076d3d",
"class":"cell txt l",
"children":[
"Use for significant exacerbations of COPD; avoid, if possible, in stable COPD to limit glucocorticoid toxicity; consider inhaled glucocorticoids to facilitate weaning of systemic glucocorticoids"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"3"
},
"children":[
" ",
{
"type":"p",
"hlId":"4172b5",
"class":"col hd l",
"children":[
"Combination Agents"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"23383f",
"class":"cell txt l",
"children":[
"Combined inhaled long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist and inhaled glucocorticoid in a single inhaler (fluticasone/salmeterol, budesonide/formoterol, mometasone/formoterol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc0709",
"class":"cell txt l",
"children":[
"Combined short-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist plus short-acting anticholinergic in a single inhaler (fenoterol/ipratropium, albuterol/ipratropium)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13ef17",
"class":"cell txt l",
"children":[
"Generally used as needed for mild disease with few symptoms; avoid using both short- and long-acting anticholinergics; this combination therapy may be used for maintenance therapy only if patients have well-controlled disease on this combination treatment and do not require rescue therapy if/when expense is a determining factor"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80f2cd",
"class":"cell txt l",
"children":[
"Combined inhaled glucocorticoid and ultra-long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist in a single inhaler (fluticasone/vilanterol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97eebf",
"class":"cell txt l",
"children":[
"Not to be used for treatment of acute bronchospasm"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50f39f",
"class":"cell txt l",
"children":[
"Combined long-acting anticholinergic plus ultra-long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist in a single inhaler (umeclidinium/vilanterol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f903d3",
"class":"cell txt l",
"children":[
"Not to be used for treatment of acute bronchospasm; avoid using both short- and long-acting anticholinergics"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3605a",
"class":"cell txt l",
"children":[
"Combined long-acting anticholinergic plus long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist in a single inhaler (olodaterol/glycopyrrolate, indacaterol/glycopyrrolate, glycopyrrolate/formoterol, olodaterol/tiotropium)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f903d3",
"class":"cell txt l",
"children":[
"Not to be used for treatment of acute bronchospasm; avoid using both short- and long-acting anticholinergics"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_4-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"986191",
"class":"cell txt l",
"children":[
"Combined long-acting anticholinergic plus long-acting β",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-agonist plus inhaled corticosteroid in a single inhaler (fluticasone/umeclidinium/vilanterol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac4caa",
"class":"cell txt l",
"children":[
"Same/combined effects of both drug classes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f903d3",
"class":"cell txt l",
"children":[
"Not to be used for treatment of acute bronchospasm; avoid using both short- and long-acting anticholinergics"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_pm_t14":{
"id":"mk19_b_pm_t14",
"number":14,
"bookId":"pm",
"title":{
"__html":"Common Causes of Bronchiectasis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b3e9c0",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 14. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t14"
}
]
},
"Common Causes of Bronchiectasis"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6b652",
"class":"cell txt l",
"children":[
"Airway obstruction"
]
},
" ",
{
"type":"p",
"hlId":"2652d1",
"class":"cell txt li",
"children":[
"Tumor"
]
},
" ",
{
"type":"p",
"hlId":"951bd5",
"class":"cell txt li",
"children":[
"Foreign body"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f361f",
"class":"cell txt l",
"children":[
"Aspiration"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b576de",
"class":"cell txt l",
"children":[
"COPD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f16ef1",
"class":"cell txt l",
"children":[
"Congenital"
]
},
" ",
{
"type":"p",
"hlId":"342749",
"class":"cell txt li",
"children":[
"Mounier-Kuhn syndrome (congenital tracheobronchomegaly)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37c530",
"class":"cell txt l",
"children":[
"Autoimmune disorders"
]
},
" ",
{
"type":"p",
"hlId":"a24b15",
"class":"cell txt li",
"children":[
"Rheumatoid arthritis"
]
},
" ",
{
"type":"p",
"hlId":"9d8ae5",
"class":"cell txt li",
"children":[
"Sjögren's syndrome"
]
},
" ",
{
"type":"p",
"hlId":"271f14",
"class":"cell txt li",
"children":[
"Inflammatory bowel disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"825a2f",
"class":"cell txt l",
"children":[
"Hypersensitivity"
]
},
" ",
{
"type":"p",
"hlId":"f41915",
"class":"cell txt li",
"children":[
"Allergic bronchopulmonary aspergillosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec0f85",
"class":"cell txt l",
"children":[
"Immunodeficiency"
]
},
" ",
{
"type":"p",
"hlId":"eebe9f",
"class":"cell txt li",
"children":[
"Common variable immunodeficiency"
]
},
" ",
{
"type":"p",
"hlId":"abc5a5",
"class":"cell txt li",
"children":[
"HIV"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e1755",
"class":"cell txt l",
"children":[
"Mucociliary dysfunction"
]
},
" ",
{
"type":"p",
"hlId":"281637",
"class":"cell txt li",
"children":[
"Cystic fibrosis"
]
},
" ",
{
"type":"p",
"hlId":"56e267",
"class":"cell txt li",
"children":[
"Primary ciliary dyskinesia"
]
},
" ",
{
"type":"p",
"hlId":"aaf365",
"class":"cell txt li",
"children":[
"Young syndrome (bronchiectasis, sinusitis, and obstructive azoospermia and no evidence of cystic fibrosis)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c9b35",
"class":"cell txt l",
"children":[
"Infection-related"
]
},
" ",
{
"type":"p",
"hlId":"432448",
"class":"cell txt li",
"children":[
"Tuberculosis"
]
},
" ",
{
"type":"p",
"hlId":"fadc33",
"class":"cell txt li",
"children":[
"Nontuberculous mycobacteria"
]
},
" ",
{
"type":"p",
"hlId":"ceef6f",
"class":"cell txt li",
"children":[
"Pneumonia, especially recurrent"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}